LEGISLATURE OF THE STATE OF IDAHO
Sixty-eighth Legislature First Regular Session - 2025
IN THE HOUSE OF REPRESENTATIVES
HOUSE BILL NO. 401
BY REDMAN AND RUBEL
1 AN ACT
2 RELATING TO THE SERGEANT KITZHABER MEDICAL CANNABIS ACT; AMENDING TITLE 39,
3 IDAHO CODE, BY THE ADDITION OF A NEW CHAPTER 96, TITLE 39, IDAHO CODE,
4 TO PROVIDE A SHORT TITLE AND LEGISLATIVE INTENT, TO PROVIDE FOR STATU-
5 TORY CONSTRUCTION, TO DEFINE TERMS, TO AUTHORIZE THE USE OF CANNABIS AND
6 CANNABIS PRODUCTS AND RELATED ACTIVITIES UNDER CERTAIN CIRCUMSTANCES,
7 TO PROVIDE FOR AN ELECTRONIC VERIFICATION SYSTEM AND PENALTIES, TO
8 ESTABLISH PROVISIONS REGARDING QUALIFYING CONDITIONS, TO ESTABLISH
9 PROVISIONS REGARDING PRACTITIONER REGISTRATION, TRAINING, AND TREAT-
10 MENT RECOMMENDATIONS, TO ESTABLISH PROVISIONS REGARDING LIMITATIONS
11 ON LIABILITY AND THE STANDARD OF CARE, TO PROVIDE FOR A QUALIFIED PA-
12 TIENT ENTERPRISE FUND AND REVENUE NEUTRALITY, TO ESTABLISH PROVISIONS
13 REGARDING NONDISCRIMINATION, TO CLARIFY THAT INSURERS AND OTHERS ARE
14 NOT REQUIRED TO COVER CANNABIS, CANNABIS PRODUCTS, OR MEDICAL CANNABIS
15 DEVICES, TO ESTABLISH PROVISIONS REGARDING THE USE OF HEMP EXTRACT,
16 CANNABIDIOL, AND CERTAIN OTHER PRODUCTS, TO ESTABLISH PROVISIONS
17 REGARDING MEDICAL CANNABIS PATIENT CARDS, TO ESTABLISH PROVISIONS RE-
18 GARDING MEDICAL CANNABIS CAREGIVER CARDS, TO PROVIDE FOR A CRIMINAL
19 HISTORY AND BACKGROUND CHECK OF A DESIGNATED CAREGIVER, TO ESTABLISH
20 PROVISIONS REGARDING MEDICAL CANNABIS CARD REQUIREMENTS AND A REBUT-
21 TABLE PRESUMPTION, TO ESTABLISH PROVISIONS REGARDING A LOST OR STOLEN
22 MEDICAL CANNABIS CARD, TO PROVIDE FOR THE IMPORTATION AND TRANSPORTA-
23 TION OF CANNABIS, CANNABIS PRODUCTS, AND MEDICAL CANNABIS DEVICES, TO
24 PROVIDE FOR CRIMINAL ENFORCEMENT, TO PROVIDE FOR A REPORT, TO PROVIDE
25 FOR RULEMAKING AUTHORITY AND FOR CERTAIN TRAINING, TO PROVIDE LEGAL IM-
26 MUNITIES, TO PROVIDE THAT CERTAIN ACTIVITIES ARE NOT PERMITTED, TO PRO-
27 VIDE FOR PENALTIES, TO PROVIDE PROHIBITIONS, TO PROVIDE PROTECTIONS,
28 AND TO PROVIDE SEVERABILITY; AMENDING SECTION 37-2705, IDAHO CODE, TO
29 REMOVE PROVISIONS FROM SCHEDULE I IN THE UNIFORM CONTROLLED SUBSTANCES
30 ACT; AMENDING SECTION 37-2707, IDAHO CODE, TO REVISE PROVISIONS RE-
31 GARDING SCHEDULE II IN THE UNIFORM CONTROLLED SUBSTANCES ACT; AMENDING
32 SECTION 37-2732, IDAHO CODE, TO PROVIDE EXCEPTIONS AND APPLICABILITY;
33 AMENDING SECTION 37-2732B, IDAHO CODE, TO PROVIDE AN EXCEPTION; AMEND-
34 ING SECTION 25-2703, IDAHO CODE, TO PROVIDE A CORRECT CODE REFERENCE;
35 AND DECLARING AN EMERGENCY.
36 Be It Enacted by the Legislature of the State of Idaho:
37 SECTION 1. That Title 39, Idaho Code, be, and the same is hereby amended
38 by the addition thereto of a NEW CHAPTER, to be known and designated as Chap-
39 ter 96, Title 39, Idaho Code, and to read as follows:
40 CHAPTER 96
41 SERGEANT KITZHABER MEDICAL CANNABIS ACT

2
1 39-9601. SHORT TITLE -- LEGISLATIVE INTENT -- STATUTORY CONSTRUC-
2 TION. (1) This chapter shall be known and may be cited as the "Sergeant
3 Kitzhaber Medical Cannabis Act."
4 (2) In enacting this chapter, it is the intent of the legislature to
5 authorize the possession, transportation, and use of cannabis and cannabis
6 products, within the limits prescribed by this chapter, for the purpose of
7 making medical cannabis treatment available to Idaho patients suffering
8 from serious health conditions. Persons whose actions are permitted by and
9 in compliance with the provisions of this chapter will not, for such actions,
10 be held to violate the provisions of chapter 27, title 37, Idaho Code, or
11 any other provision of state law, local ordinance, or administrative rule
12 contrary to the provisions of this chapter.
13 (3) The provisions of this chapter should be construed in the light most
14 consistent with the intent provided in this section.
15 39-9602. DEFINITIONS. For the purposes of this chapter, unless con-
16 text otherwise requires:
17 (1) "Blister" means a plastic cavity or pocket used to contain no more
18 than a single dose of cannabis or a cannabis product in a blister pack.
19 (2) "Blister pack" means a plastic, paper, or foil package with mul-
20 tiple blisters each containing no more than a single dose of cannabis or a
21 cannabis product.
22 (3) "Board" means the board of pharmacy or the division of occupational
23 and professional licenses acting on behalf of the board of pharmacy.
24 (4) "Cannabidiol" or "CBD" means a nonintoxicating cannabinoid found
25 in cannabis and hemp.
26 (5) "Cannabis" means marijuana as defined in section 37-2701, Idaho
27 Code.
28 (6) "Cannabis product" means a product derived from, or made by, pro-
29 cessing cannabis plants or parts of the plant that:
30 (a) Is intended for human use; and
31 (b) Contains cannabis or tetrahydrocannabinol.
32 (7) "Community location" means a public or private school, a church, a
33 public library, a public playground, or a public park.
34 (8) "Department" means the state department of health and welfare.
35 (9) "Designated caregiver" means an individual who:
36 (a) Is designated by a patient with a medical cannabis patient card as
37 the patient's caregiver; and
38 (b) Registers with the department pursuant to section 39-9613, Idaho
39 Code.
40 (10) "Dosing parameters" means quantity, routes, and frequency of ad-
41 ministration for a recommended treatment of cannabis in a medicinal dosage
42 form or a cannabis product in a medicinal dosage form.
43 (11) "Electronic verification system" means the system established by
44 section 39-9604, Idaho Code.
45 (12) "Licensed medical cannabis pharmacist" or "medical cannabis phar-
46 macist" means an individual licensed under chapter 17, title 54, Idaho Code,
47 who is employed by a medical cannabis pharmacy.

3
1 (13) "Licensed mental health therapist" means an individual licensed
2 under title 54, Idaho Code, who provides mental health services within the
3 scope of the individual's license.
4 (14) "Marijuana" has the same meaning as provided in section 37-2701,
5 Idaho Code.
6 (15) "Medical cannabis" means cannabis in a medicinal dosage form or a
7 cannabis product in a medicinal dosage form.
8 (16) "Medical cannabis card" means a medical cannabis patient card or a
9 medical cannabis caregiver card.
10 (17) "Medical cannabis cardholder" means the holder of a medical
11 cannabis card.
12 (18) "Medical cannabis caregiver card" means an official card that:
13 (a) The department issues to an individual whom a medical cannabis pa-
14 tient cardholder designates as a designated caregiver; and
15 (b) Is connected to the electronic verification system.
16 (19) "Medical cannabis device" means a device used to grind, inhale, or
17 ingest cannabis in a medicinal dosage form or a cannabis product in a medic-
18 inal dosage form or a device used specifically for the mechanical vaporiza-
19 tion of raw, unprocessed cannabis flower.
20 (20) "Medical cannabis patient card" means an official card that:
21 (a) The department issues to an individual with a qualifying condition;
22 and
23 (b) Is connected to the electronic verification system.
24 (21) "Medical cannabis treatment" means cannabis in a medicinal dosage
25 form, a cannabis product in a medicinal dosage form, or a medical cannabis
26 device.
27 (22) "Medicinal dosage form" means cannabis or a cannabis product in
28 a form suitable for medical treatment as described in paragraphs (a), (b),
29 and (c) of this subsection. The three (3) separate categories of medicinal
30 dosage form may be prescribed and obtained by category or by a combination of
31 categories. All forms must be packaged in single or multiple dosage forms
32 with specific and consistent cannabinoid content as provided in this subsec-
33 tion.
34 (a) "Liquid processed form of medical cannabis" means:
35 (i) A concentrated oil not to exceed one hundred (100) millili-
36 ters per container;
37 (ii) A liquid suspension not to exceed one hundred (100) millili-
38 ters per container;
39 (iii) A topical preparation not to exceed one hundred (100) milli-
40 liters per container; or
41 (iv) A sublingual preparation not to exceed one hundred (100) mil-
42 liliters per container.
43 (b) "Solid processed form of medical cannabis" means:
44 (i) A tablet, up to ten (10) tablets per package;
45 (ii) A capsule, up to ten (10) capsules per package;
46 (iii) A gelatinous cube, gelatinous rectangular cuboid, or
47 lozenge in a cube or rectangular cuboid shape, up to ten (10) per
48 package;
49 (iv) Butter, resin, or wax not to exceed one hundred (100) grams
50 total weight per package or container; or

4
1 (v) A transdermal preparation not to exceed one hundred (100) mil-
2 ligrams per container.
3 (c) "Unprocessed medical cannabis flower" is a general term that means
4 the trichome-covered part of a female cannabis plant. It must be pack-
5 aged in a blister pack or tamper-evident package or container. Each in-
6 dividual blister or tamper-evident package or container must:
7 (i) Contain a specific and consistent weight that does not exceed
8 one (1) gram per each individual blister pack and five (5) grams
9 per complete package or does not exceed two (2) grams per tamper-
10 evident package or container and that varies by no more than ten
11 percent (10%) from the stated weight; and
12 (ii) Be labeled with a barcode that provides information con-
13 nected to an inventory control system and the individual blister's
14 content and weight or tamper-evident package's or container's
15 content and weight.
16 (d) A medicinal dosage form must be measured in grams, milligrams, or
17 milliliters.
18 (e) "Medicinal dosage form" includes a portion of unprocessed cannabis
19 flower that:
20 (i) The medical cannabis cardholder has recently removed from the
21 blister pack for use; and
22 (ii) Does not exceed the quantity described in this subsection.
23 (f) "Medicinal dosage form" does not include:
24 (i) Any unprocessed cannabis flower outside of the blister or
25 tamper-evident package or container, except as otherwise provided
26 in this subsection; or
27 (ii) A process of vaporizing concentrated cannabis oil via a car-
28 tridge or other similar product or device by placing the concen-
29 trated cannabis oil cartridge or other similar product or device
30 in a vape or vaping device.
31 (23) "Person" means:
32 (a) An individual, a facility, a partnership, an association, a firm, a
33 trust, a limited liability company, or a corporation; or
34 (b) An agent or an employee of an individual, a facility, a partnership,
35 an association, a firm, a trust, a limited liability company, or a cor-
36 poration.
37 (24) "Practitioner" has the same meaning as provided in section
38 54-1704, Idaho Code.
39 (25) "Qualified patient enterprise fund" means the fund established in
40 section 39-9608, Idaho Code.
41 (26) "Qualifying condition" means a condition described in section
42 39-9605, Idaho Code.
43 (27) "Tetrahydrocannabinol" or "THC" means a substance derived from
44 cannabis and contained in a plant of the genus Cannabis, as well as synthetic
45 equivalents of the substances contained in the cannabis plant, or in the
46 resinous extractives of Cannabis, sp. and/or synthetic substances, deriva-
47 tives, and their isomers with similar chemical structure as described in
48 section 37-2707(i), Idaho Code.

5
1 39-9603. AUTHORIZATION. Notwithstanding any provision of law to the
2 contrary, the possession, transportation, and use of cannabis and cannabis
3 products, as well as activities related to the possession, transportation,
4 and use of cannabis and cannabis products, are authorized as provided in this
5 chapter for the purposes identified in this chapter.
6 39-9604. ELECTRONIC VERIFICATION SYSTEM -- PENALTIES. (1) The board
7 shall establish an electronic verification system that complies with the
8 provisions of this section. An existing system may be used or adapted to
9 comply with the provisions of this section. The board may, as necessary:
10 (a) Coordinate with the division of purchasing to develop a solicita-
11 tion for a third-party provider to develop and maintain the electronic
12 verification system; and
13 (b) Select a third-party provider who meets the requirements contained
14 in the solicitation issued under paragraph (a) of this subsection.
15 (2) The board must ensure that, on or before January 1, 2026, the elec-
16 tronic verification system:
17 (a) Allows an individual or a practitioner acting on the individual's
18 behalf to apply for a medical cannabis patient card;
19 (b) Allows an individual to apply to renew a medical cannabis patient
20 card in accordance with section 39-9612, Idaho Code;
21 (c) Allows a practitioner to access the electronic verification system
22 in accordance with board rule;
23 (d) Provides access to:
24 (i) The board to the extent necessary to carry out the board's
25 functions and responsibilities under this chapter;
26 (ii) The department to the extent necessary to carry out the de-
27 partment's functions and responsibilities under this chapter; and
28 (iii) Licensing boards for practitioners as provided in board
29 rule;
30 (e) Provides access to state or local law enforcement; and
31 (f) Creates a record each time a person accesses the database that iden-
32 tifies the person who accesses the database and the individual whose
33 records the person accesses.
34 (3) The board may release de-identified data that the system collects
35 for the purpose of:
36 (a) Conducting medical research; and
37 (b) Providing the report required by section 39-9619, Idaho Code.
38 (4) The board shall promulgate rules, subject to legislative approval,
39 to establish:
40 (a) The limitations on access to the data in the electronic verifica-
41 tion system as described in this section; and
42 (b) Standards and procedures to ensure accurate identification of an
43 individual requesting information or receiving information as provided
44 in this section.
45 (5)(a) Any person who knowingly and intentionally releases any infor-
46 mation in the electronic verification system in violation of this sec-
47 tion is guilty of a misdemeanor.
48 (b) Any person who recklessly or with gross negligence releases any
49 information in the electronic verification system in violation of this

6
1 section is guilty of an infraction. The board shall establish such in-
2 fraction penalties in rule, subject to legislative approval.
3 (6)(a) Any person who obtains or attempts to obtain information from
4 the electronic verification system by misrepresentation or fraud is
5 guilty of a misdemeanor.
6 (b) Any person who obtains or attempts to obtain information from the
7 electronic verification system for a purpose other than a purpose this
8 chapter authorizes is guilty of a misdemeanor.
9 (7)(a) Except as provided in paragraph (e) of this subsection, a person
10 may not knowingly and intentionally use, release, publish, or otherwise
11 make available to any other person information obtained from the elec-
12 tronic verification system for any purpose other than a purpose speci-
13 fied in this section.
14 (b) Each separate violation of this subsection is:
15 (i) A misdemeanor; and
16 (ii) Subject to a civil penalty not to exceed five thousand dol-
17 lars ($5,000).
18 (c) The board shall determine a civil violation of this subsection in
19 accordance with chapter 52, title 67, Idaho Code.
20 (d) Civil penalties assessed under this subsection shall be deposited
21 into the qualified patient enterprise fund established by section
22 39-9608, Idaho Code.
23 (e) This subsection does not prohibit a person who obtains information
24 from the electronic verification system under subsection (2)(a), (c),
25 or (f) of this section from:
26 (i) Including the information in the person's medical chart or
27 file for access by a person authorized to review the medical chart
28 or file;
29 (ii) Providing the information to a person in accordance with the
30 requirements of the health insurance portability and accountabil-
31 ity act of 1996; or
32 (iii) Discussing or sharing that information on the patient with
33 the patient.
34 39-9605. QUALIFYING CONDITIONS. (1) By designating a particular con-
35 dition under subsection (2) of this section for which the use of medical
36 cannabis to treat symptoms is decriminalized, the legislature does not con-
37 clusively state that:
38 (a) Current scientific evidence clearly supports the efficacy of a med-
39 ical cannabis treatment for the condition; or
40 (b) A medical cannabis treatment will treat, cure, or positively affect
41 the condition.
42 (2) For the purposes of this chapter, each of the following conditions
43 can be considered a qualifying condition if the condition is active:
44 (a) Acquired immune deficiency syndrome (AIDS) or human immunodefi-
45 ciency virus (HIV);
46 (b) Alzheimer's disease;
47 (c) Amyotrophic lateral sclerosis (ALS);
48 (d) Autism;
49 (e) Cachexia;

7
1 (f) Cancer;
2 (g) Chronic pain;
3 (h) Crohn's disease or ulcerative colitis;
4 (i) Epilepsy or debilitating seizures;
5 (j) Multiple sclerosis or debilitating muscle spasms;
6 (k) Nausea that is not significantly responsive to traditional treat-
7 ment, except for nausea related to:
8 (i) Pregnancy;
9 (ii) Cannabis-induced cyclical vomiting syndrome; or
10 (iii) Cannabinoid hyperemesis syndrome;
11 (l) Post-traumatic stress disorder (PTSD) that is being treated and
12 monitored by a licensed mental health therapist and that:
13 (i) Has been diagnosed by a health care provider or mental health
14 provider employed or contracted by the United States department of
15 veterans affairs; or
16 (ii) Has been diagnosed or confirmed by a provider who is:
17 1. A licensed board-eligible or board-certified psychia-
18 trist;
19 2. A licensed psychologist with a doctorate-level degree;
20 3. A licensed clinical social worker with a doctorate-level
21 degree; or
22 4. A licensed advanced practice registered nurse who is
23 qualified to practice within the psychiatric mental health
24 nursing specialty;
25 (m) A terminal illness where the patient's condition is not expected to
26 improve with or without other medical treatments;
27 (n) A condition resulting in the individual receiving hospice care;
28 (o) A rare condition or disease that:
29 (i) Affects fewer than two hundred thousand (200,000) individu-
30 als in the United States, as defined in section 526 of the federal
31 food, drug, and cosmetic act; and
32 (ii) Is not adequately managed despite treatment attempts using:
33 1. Conventional medications other than opioids or opiates;
34 or
35 2. Physical interventions; or
36 (p) Another debilitating medical condition as determined by a practi-
37 tioner.
38 39-9606. PRACTITIONER REGISTRATION -- TRAINING -- TREATMENT RECOM-
39 MENDATION. (1) A practitioner may not recommend a medical cannabis treatment
40 unless the board registers the practitioner in accordance with this section.
41 (2) The board shall, within fifteen (15) days after the day on which
42 the board receives a completed application from a practitioner, register the
43 practitioner if the practitioner:
44 (a) Provides to the board the practitioner's name and address;
45 (b) Provides to the board a report detailing the practitioner's comple-
46 tion of the training requirements described in subsection (3) of this
47 section; and
48 (c) Provides to the board evidence that the practitioner:
49 (i) Has the authority to write a prescription;

8
1 (ii) Is licensed to prescribe a controlled substance; and
2 (iii) Has the authority, in accordance with the individual's scope
3 of practice, to prescribe a schedule II controlled substance.
4 (3) As a condition precedent to registration, a practitioner must com-
5 plete training as determined by the board in cooperation with other applica-
6 ble licensing boards, which training must cover:
7 (a) The provisions of this chapter;
8 (b) General information about medical cannabis under federal and state
9 law;
10 (c) The latest scientific research on the endocannabinoid system and
11 medical cannabis, including risks and benefits;
12 (d) Recommendations for medical cannabis as it relates to the continu-
13 ing care of a patient in pain management, risk management, potential ad-
14 diction, or palliative care;
15 (e) Best practices for recommending the form and dosage of medical
16 cannabis products based on the qualifying condition underlying a medi-
17 cal cannabis recommendation; and
18 (f) Other information as determined by the board, in cooperation with
19 applicable licensing boards.
20 (4) A practitioner may recommend medical cannabis to an individual un-
21 der this chapter in the course of a provider-patient relationship only af-
22 ter the practitioner has completed and documented in the patient's medical
23 record a thorough assessment of the patient's condition and medical history
24 based on the appropriate standard of care for the patient's condition.
25 (5)(a) Except as provided in paragraph (b) of this subsection, a prac-
26 titioner may not advertise that the practitioner recommends medical
27 cannabis treatment.
28 (b) For purposes of paragraph (a) of this subsection, the communication
29 of the following through a website does not constitute advertising:
30 (i) A qualifying condition that the practitioner treats;
31 (ii) A scientific study regarding medical cannabis use; or
32 (iii) Information about a product or service offered by the prac-
33 titioner.
34 (6)(a) A practitioner's registration under this section expires two
35 (2) years after the day on which the board issues the registration.
36 (b) The board shall renew a practitioner's registration if the practi-
37 tioner:
38 (i) Applies for renewal;
39 (ii) Is eligible for a registration under this section, includ-
40 ing maintaining an unrestricted license as described in subsec-
41 tion (2) of this section;
42 (iii) Certifies to the board in a completed renewal application
43 that the information required in subsection (2) of this section is
44 accurate or updates the information; and
45 (iv) Submits a report detailing the completion of any training for
46 renewal as may be required by the board.
47 (7) The board may revoke the registration of a practitioner who fails to
48 maintain compliance with the requirements of this section.
49 (8) A practitioner may not receive any compensation or benefit for the
50 practitioner's medical cannabis treatment recommendation from:

9
1 (a) A medical cannabis pharmacy or an owner, an officer, a director, a
2 board member, an employee, or an agent of a medical cannabis pharmacy;
3 or
4 (b) Another practitioner.
5 39-9607. LIMITATIONS ON LIABILITY -- STANDARD OF CARE. (1) A practi-
6 tioner described in subsection (2) of this section is not subject to the fol-
7 lowing solely for violating a federal law or regulation that would otherwise
8 prohibit recommending, prescribing, or dispensing medical cannabis, a med-
9 ical cannabis product, or a cannabis-based drug that the United States food
10 and drug administration has not approved:
11 (a) Civil or criminal liability; or
12 (b) Licensure sanctions under title 54, Idaho Code.
13 (2) The limitations of liability described in subsection (1) of this
14 section apply to:
15 (a) A practitioner who recommends a medical cannabis treatment to a pa-
16 tient; or
17 (b) A licensed medical cannabis pharmacist or medical cannabis phar-
18 macy nurse who dispenses, in a medical cannabis pharmacy, treatment
19 with cannabis in a medicinal dosage form or a cannabis product in a
20 medicinal dosage form to a medical cannabis cardholder in accordance
21 with this chapter.
22 (3) Nothing in this section or chapter reduces or in any way negates the
23 duty of an individual described in subsection (2) of this section to use rea-
24 sonable and ordinary care in the treatment of a patient who may have a quali-
25 fying condition and:
26 (a) For whom a practitioner has recommended or might consider recom-
27 mending a medical cannabis treatment; or
28 (b) With whom a licensed medical cannabis pharmacist or medical
29 cannabis pharmacy nurse has interacted in the dosing or dispensing of
30 cannabis or a cannabis product.
31 39-9608. QUALIFIED PATIENT ENTERPRISE FUND -- REVENUE NEUTRALITY. (1)
32 There is hereby established in the state treasury the qualified patient en-
33 terprise fund.
34 (2) Moneys in the fund established by this section shall consist of:
35 (a) Moneys deposited in the fund under this chapter;
36 (b) Appropriations the legislature makes to the fund;
37 (c) Civil penalties assessed pursuant to section 39-9604, Idaho Code;
38 and
39 (d) The interest described in subsection (3) of this section.
40 (3) Interest earned on idle moneys in the fund shall be deposited in the
41 fund.
42 (4) The board may use moneys in the fund only to fund the board's re-
43 sponsibilities under this chapter. The board shall reimburse the department
44 from the fund for the department's administrative expenses under this chap-
45 ter.
46 (5) Fees authorized by this chapter shall be set in amounts necessary,
47 in total, to cover expenses related to implementation and enforcement of
48 this chapter.

10
1 39-9609. NONDISCRIMINATION FOR MEDICAL CARE OR GOVERNMENT EMPLOY-
2 MENT. (1) For purposes of medical care, including an organ transplant, a
3 patient's use, in accordance with this chapter, of cannabis in a medicinal
4 dosage form or a cannabis product in a medicinal dosage form:
5 (a) Is considered the equivalent of the authorized use of any other med-
6 ication used at the discretion of a physician; and
7 (b) Does not constitute the use of an illicit substance or otherwise
8 disqualify an individual from needed medical care.
9 (2)(a) Notwithstanding any other provision of law and except as pro-
10 vided in paragraph (b) of this subsection, the state or any political
11 subdivision must treat an employee's use of medical cannabis in accor-
12 dance with this chapter in the same way the state or political subdivi-
13 sion treats employee use of opioids and opiates.
14 (b) Paragraph (a) of this subsection does not apply where application
15 would jeopardize federal funding for the employee's position.
16 39-9610. NO INSURANCE REQUIREMENT. Nothing in this chapter requires
17 an insurer, a third-party administrator, or an employer to pay for or reim-
18 burse purchase of cannabis, a cannabis product, or a medical cannabis de-
19 vice.
20 39-9611. NO EFFECT ON USE OF HEMP EXTRACT -- CANNABIDIOL -- APPROVED
21 DRUGS. (1) Nothing in this chapter prohibits an individual:
22 (a) From purchasing, selling, possessing, administering, or using hemp
23 extract that is legal under federal law; or
24 (b) From purchasing, selling, possessing, administering, or using a
25 cannabidiol product that is approved by the United States food and drug
26 administration.
27 (2) Nothing in this chapter restricts or otherwise affects the pre-
28 scription, distribution, or dispensing of a product that the United States
29 food and drug administration has approved.
30 39-9612. MEDICAL CANNABIS PATIENT CARD -- FEES -- STUDIES. (1) Effec-
31 tive January 1, 2026, the department shall issue a medical cannabis patient
32 card or a caregiver card to an individual described in subsection (2) of this
33 section within fifteen (15) days after the day on which an individual who
34 satisfies the eligibility criteria in this section or section 39-9613, Idaho
35 Code, submits a completed application in accordance with this section or
36 section 39-9613, Idaho Code.
37 (2) An individual is eligible for a medical cannabis patient card if:
38 (a) The individual is at least twenty-one (21) years of age;
39 (b) The individual is an Idaho resident;
40 (c) The individual's practitioner recommends treatment with medical
41 cannabis in accordance with subsection (4) of this section;
42 (d) The individual signs an acknowledgment stating that the individual
43 received the information described in subsection (8) of this section;
44 and
45 (e) The individual pays to the department a fee in an amount set by the
46 department.

11
1 (3) An individual who is eligible for a medical cannabis card pursuant
2 to subsection (2) of this section or the individual's practitioner acting on
3 the individual's behalf shall submit an application for a medical cannabis
4 card to the department:
5 (a) Through an electronic application connected to the electronic ver-
6 ification system; and
7 (b) With information including:
8 (i) The applicant's name, gender, age, and address; and
9 (ii) The number of the applicant's form of identification that is
10 a valid United States federal- or state-issued photo identifica-
11 tion, including a driver's license, a United States passport, a
12 United States passport card, or a United States military identifi-
13 cation card.
14 (4) To recommend a medical cannabis treatment to a patient or to renew a
15 recommendation, a practitioner must:
16 (a) Before recommending cannabis in a medicinal dosage form or a
17 cannabis product in a medicinal dosage form:
18 (i) Verify the patient's valid form of identification described
19 in subsection (3) of this section;
20 (ii) Review any record related to the patient in:
21 1. The electronic verification system; and
22 2. Other databases regarding other controlled substance
23 prescriptions or criminal violations where controlled sub-
24 stances are involved; and
25 (iii) Consider the recommendation in light of the patient's qual-
26 ifying condition and history of medical cannabis and controlled
27 substance use; and
28 (b) State in the practitioner's recommendation that the patient:
29 (i) Suffers from a qualifying condition, including the type of
30 qualifying condition;
31 (ii) May benefit from treatment with cannabis or a cannabis prod-
32 uct in a specific medicinal dosage form. The practitioner must
33 state the medicinal dosage form the patient is authorized to use.
34 Practitioners may select one (1), two (2), or all three (3) cate-
35 gories of medical cannabis, which are:
36 1. Liquid processed form of medical cannabis;
37 2. Solid processed form of medical cannabis; and
38 3. Unprocessed medical cannabis flower.
39 (5) A medical cannabis card that the department issues under this sec-
40 tion is valid for the lesser of:
41 (a) An amount of time that the practitioner determines; or
42 (b) Twelve (12) months.
43 (6)(a) A medical cannabis patient card is renewable if, at the time of
44 renewal, the cardholder meets the requirements of subsection (2) of
45 this section.
46 (b) A cardholder described in paragraph (a) of this subsection may re-
47 new a medical cannabis patient card according to a process established
48 by the department.
49 (c) A cardholder under subsection (2) of this section who renews a med-
50 ical cannabis patient card must pay to the department a renewal fee in

12
1 an amount set by the department, which may not exceed the cost of the
2 relatively lower administrative burden of renewal in comparison to the
3 original application process.
4 (7)(a) A cardholder under this section must carry the cardholder's
5 valid medical cannabis card with the patient's name when engaging in
6 activities authorized by this chapter.
7 (b)(i) A cardholder under this section may possess or transport,
8 in accordance with this chapter and the recommendation underlying
9 the card, cannabis in a medicinal dosage form, a cannabis product
10 in a medicinal dosage form, or a medical cannabis device.
11 (ii) To address the qualifying condition underlying the medical
12 cannabis treatment recommendation, a medical cannabis patient
13 cardholder may use cannabis in a medicinal dosage form, a medical
14 cannabis product in a medicinal dosage form, or a medical cannabis
15 device.
16 (c) If a licensed medical cannabis pharmacy is not operating within the
17 state on and after January 1, 2026, or is operating in the state but not
18 within one hundred (100) miles of a cardholder's physical address, a
19 cardholder under this section is not subject to prosecution for the pos-
20 session of up to a sixty (60) day supply of medical cannabis, including:
21 (i) No more than four thousand (4,000) milligrams of THC, which
22 may be in solid processed form of medical cannabis, liquid pro-
23 cessed form of medical cannabis, or a combination of both. The
24 CBD-to-THC ratio in the medical cannabis shall be determined by
25 the relevant practitioner. The product must display a label that
26 clearly shows the amount of tetrahydrocannabinol and cannabidiol
27 in the specific medical cannabis form;
28 (ii) No more than sixty (60) grams of unprocessed medical cannabis
29 flower containing twenty-two percent (22%) or less THC;
30 (iii) If a terminally ill, hospice, or cancer patient with the au-
31 thorization of the practitioner, up to twenty thousand (20,000)
32 milligrams of THC in processed medical cannabis where each indi-
33 vidual serving of the processed medical cannabis contains no more
34 than one hundred (100) milligrams of THC; or
35 (iv) Marijuana drug paraphernalia.
36 (8) The department, in cooperation with the board, shall establish by
37 rule, subject to legislative approval, a process to provide information re-
38 garding the following to an individual receiving a medical cannabis card:
39 (a) Risks associated with medical cannabis treatment;
40 (b) The fact that a condition's listing as a qualifying condition does
41 not suggest that medical cannabis treatment is an effective treatment
42 or cure for that condition; and
43 (c) Other relevant warnings and safety information.
44 (9) The department may establish procedures by rule to implement the
45 application and issuance provisions of this section.
46 (10)(a) A person may submit to the department a request to conduct a
47 medical research study using medical cannabis cardholder data that the
48 electronic verification system contains.

13
1 (b) The department, in cooperation with the board, will review a
2 request described in paragraph (a) of this subsection to determine
3 whether the medical research study is valid.
4 (c) If the department and the board make a determination under para-
5 graph (b) of this subsection that the medical research study is valid,
6 the department shall notify each relevant cardholder asking for the
7 cardholder's consent to participate in the study.
8 (d) The department may release, for the purposes of a study described in
9 this subsection, information about a cardholder under this section who
10 consents to participate under paragraph (c) of this subsection.
11 (e) The department, in cooperation with the board, may establish stan-
12 dards for a medical research study's validity by rule, subject to leg-
13 islative approval.
14 39-9613. MEDICAL CANNABIS CAREGIVER CARD -- REGISTRATION -- RENEWAL
15 -- REVOCATION. (1) A cardholder described in section 39-9612, Idaho Code,
16 may designate up to two (2) individuals to serve as a designated caregiver
17 for the cardholder if a practitioner determines that, due to physical diffi-
18 culty or undue hardship, the cardholder needs assistance to obtain the medi-
19 cal cannabis treatment that the practitioner recommends.
20 (2) An individual who the department registers as a designated care-
21 giver under this section:
22 (a) May carry a valid medical cannabis caregiver card;
23 (b) In accordance with this chapter, may possess, transport, or assist
24 the patient in the use of cannabis in a medicinal dosage form, a cannabis
25 product in a medicinal dosage form, or a medical cannabis device on be-
26 half of the designating medical cannabis cardholder;
27 (c) May not charge a fee to an individual to act as the individual's des-
28 ignated caregiver or for a service that the designated caregiver pro-
29 vides in relation to the role as a designated caregiver;
30 (d) May accept reimbursement from the designating medical cannabis
31 cardholder for direct costs the designated caregiver incurs for assist-
32 ing with the designating cardholder's medicinal use of cannabis; and
33 (e) Is not subject to prosecution for the possession of the following,
34 if a licensed medical cannabis pharmacy is not operating within the
35 state on and after January 1, 2026, or is operating in the state but not
36 within one hundred (100) miles of a cardholder's physical address:
37 (i) No more than four thousand (4,000) milligrams of THC, which
38 may be in solid processed form of medical cannabis, liquid pro-
39 cessed form of medical cannabis, or a combination of both. The
40 CBD-to-THC ratio in the medical cannabis shall be determined by
41 the relevant practitioner. The product must display a label that
42 clearly shows the amount of tetrahydrocannabinol and cannabidiol
43 in the specific medical cannabis form;
44 (ii) No more than sixty (60) grams of unprocessed medical cannabis
45 flower containing twenty-two percent (22%) or less THC;
46 (iii) If a terminally ill, hospice, or cancer patient with the au-
47 thorization of the practitioner, up to twenty thousand (20,000)
48 milligrams of THC in processed medical cannabis where each indi-

14
1 vidual serving of the processed medical cannabis contains no more
2 than one hundred (100) milligrams of THC; or
3 (iv) Marijuana drug paraphernalia.
4 (3)(a) The department shall:
5 (i) Within fifteen (15) days after the day on which an individual
6 submits a completed application in compliance with this section,
7 issue a medical cannabis caregiver card to the applicant if the ap-
8 plicant:
9 1. Is designated as a caregiver under subsection (1) of this
10 section;
11 2. Is eligible for a medical cannabis caregiver card under
12 subsection (4) of this section; and
13 3. Complies with this section; and
14 (ii) Notify the Idaho state police of each individual that the de-
15 partment registers as a designated caregiver.
16 (b) The department must ensure that a medical cannabis caregiver card
17 contains the information described in subsection (5)(b) of this sec-
18 tion.
19 (4) An individual is eligible for a medical cannabis caregiver card if
20 the individual:
21 (a) Is at least twenty-one (21) years of age;
22 (b) Is an Idaho resident;
23 (c) Pays to the department a fee in an amount set by the department, plus
24 the cost of the criminal history and background check described in sec-
25 tion 39-9614, Idaho Code;
26 (d) Signs an acknowledgment stating that the applicant received the in-
27 formation described in section 39-9612(8), Idaho Code; and
28 (e) Has not been convicted of a misdemeanor or felony drug distribution
29 offense that is a felony under either state or federal law, unless:
30 (i) The individual completes any imposed sentence two (2) or more
31 years before the day on which the individual submits the applica-
32 tion; or
33 (ii) The offense was for conduct that is authorized under this
34 chapter.
35 (5) An eligible applicant for a medical cannabis caregiver card shall:
36 (a) Submit an application for a medical cannabis caregiver card to the
37 department through an electronic application connected to the elec-
38 tronic verification system; and
39 (b) Submit the following information in such application:
40 (i) The applicant's name, gender, age, and address; and
41 (ii) The name, gender, age, and address of the cardholder de-
42 scribed in section 39-9612, Idaho Code, who designated the appli-
43 cant.
44 (6) Except as otherwise provided by this chapter, a medical cannabis
45 caregiver card that the department issues under this section is valid for the
46 lesser of:
47 (a) An amount of time that the cardholder described in section 39-9612,
48 Idaho Code, who designated the caregiver determines; or
49 (b) The amount of time remaining before the card of the cardholder de-
50 scribed in section 39-9612, Idaho Code, expires.

15
1 (7)(a) If a designated caregiver meets the requirements of subsection
2 (4) of this section, the designated caregiver's medical cannabis care-
3 giver card renews automatically at the time the cardholder described in
4 section 39-9612, Idaho Code, who designated the caregiver:
5 (i) Renews the cardholder's card; and
6 (ii) Renews the caregiver's designation, in accordance with para-
7 graph (b) of this subsection.
8 (b) The department shall provide a method in the card renewal process
9 to allow a cardholder described in section 39-9612, Idaho Code, who has
10 designated a caregiver to:
11 (i) Signify that the cardholder renews the caregiver's designa-
12 tion;
13 (ii) Remove a caregiver's designation; or
14 (iii) Designate a new caregiver.
15 (8) The department may revoke a medical cannabis caregiver card if the
16 designated caregiver:
17 (a) Violates the provisions of this chapter; or
18 (b) Has been convicted under state or federal law for conduct that is
19 not authorized by this chapter and that is:
20 (i) A felony; or
21 (ii) After the effective date of this chapter, a misdemeanor for
22 drug distribution.
23 39-9614. DESIGNATED CAREGIVER -- CRIMINAL HISTORY AND BACKGROUND
24 CHECK. Each applicant for a medical cannabis caregiver card shall submit to a
25 criminal history and background check as determined by the department. The
26 department will assess an applicant a fee in an amount set by the department
27 for the criminal history and background check.
28 39-9615. MEDICAL CANNABIS CARD -- PATIENT AND DESIGNATED CAREGIVER
29 REQUIREMENTS -- REBUTTABLE PRESUMPTION.
30 (1)(a) A medical cannabis cardholder who possesses cannabis in a medic-
31 inal dosage form or a cannabis product in a medicinal dosage form that
32 the cardholder purchased under this chapter:
33 (i) Must carry the cardholder's medical cannabis card when engag-
34 ing in activities authorized by this chapter;
35 (ii) Must carry, with the cannabis in a medicinal dosage form or
36 cannabis product in a medicinal dosage form, a label that identi-
37 fies that the cannabis or cannabis product was sold from a licensed
38 medical cannabis pharmacy; and
39 (iii) May possess:
40 1. No more than four thousand (4,000) milligrams of THC,
41 which may be in solid processed form of medical cannabis,
42 liquid processed form of medical cannabis, or a combina-
43 tion of both. The CBD-to-THC ratio in the medical cannabis
44 shall be determined by the relevant practitioner. The prod-
45 uct must display a label that clearly shows the amount of
46 tetrahydrocannabinol and cannabidiol in the specific medi-
47 cal cannabis form;

16
1 2. No more than sixty (60) grams of unprocessed medical
2 cannabis flower containing twenty-two percent (22%) or less
3 THC; or
4 3. If a terminally ill, hospice, or cancer patient with the
5 authorization of the practitioner, up to twenty thousand
6 (20,000) milligrams of THC in processed medical cannabis
7 where each individual serving of the processed medical
8 cannabis contains no more than one hundred (100) milligrams
9 of THC.
10 (b) A medical cannabis cardholder who possesses cannabis in a medicinal
11 dosage form or a cannabis product in a medicinal dosage form in viola-
12 tion of this subsection is guilty of an infraction and subject to a fine
13 of one hundred dollars ($100).
14 (c) A medical cannabis cardholder who possesses more than the amount
15 authorized in paragraph (a)(iii) of this subsection but no more than
16 twice the amount authorized in paragraph (a)(iii) of this subsection
17 is guilty of a misdemeanor and subject to a fine of one thousand dollars
18 ($1,000).
19 (d) An individual who is guilty of a violation pursuant to paragraph (b)
20 or (c) of this subsection is not guilty of a violation of chapter 27, ti-
21 tle 37, Idaho Code, for the conduct underlying the penalty described in
22 either paragraph.
23 (e) A medical cannabis cardholder who possesses more than twice the
24 amount authorized in paragraph (a)(iii) of this subsection is subject
25 to an applicable penalty prescribed by chapter 27, title 37, Idaho Code.
26 (2) A medical cannabis patient cardholder may not combust unprocessed
27 medical cannabis flower in public or in view of the public.
28 (3) If a medical cannabis cardholder carrying the cardholder's card
29 possesses cannabis in a medicinal dosage form or a cannabis product in a
30 medicinal dosage form in compliance with the provisions of subsection (1) of
31 this section or a medical cannabis device that corresponds with the cannabis
32 or cannabis product:
33 (a) There is a rebuttable presumption that the cardholder possesses the
34 cannabis, cannabis product, or medical cannabis device legally; and
35 (b) There is no probable cause, based solely on the cardholder's pos-
36 session of the cannabis in medicinal dosage form, cannabis product in
37 medicinal dosage form, or medical cannabis device, to believe that the
38 cardholder is engaging in illegal activity.
39 (4)(a) If a peace officer stops an individual who possesses cannabis in
40 a medicinal dosage form, a cannabis product in a medicinal dosage form,
41 or a medical cannabis device and the individual represents to the peace
42 officer that the individual holds a valid medical cannabis card but the
43 individual does not have the medical cannabis card in the individual's
44 possession at the time of the stop by the peace officer, then the peace
45 officer must attempt to access the electronic verification system to
46 determine whether the individual holds a valid medical cannabis card.
47 (b) If the peace officer is able to verify that the individual described
48 in paragraph (a) of this subsection is a valid medical cannabis card-
49 holder, then the peace officer:

17
1 (i) May not arrest or take the individual into custody for the
2 sole reason that the individual is in possession of cannabis in a
3 medicinal dosage form, a cannabis product in a medicinal dosage
4 form, or a medical cannabis device; and
5 (ii) May not seize the cannabis, cannabis product, or medical
6 cannabis device.
7 (c) If the peace officer is unable to verify that the individual de-
8 scribed in paragraph (a) of this subsection is a valid medical cannabis
9 cardholder, then the peace officer may refer the individual for prose-
10 cution or issue a citation that would be appropriate under the circum-
11 stances for an individual who does not hold a valid medical cannabis
12 card. The peace officer may also seize any cannabis, cannabis product,
13 or medical cannabis device. However, the individual may not be taken
14 into custody, and any criminal complaint or citation must be dismissed
15 upon presentation of proof that the individual holds a valid medical
16 cannabis card to the prosecuting attorney with jurisdiction over the
17 complaint or citation.
18 (5) A medical cannabis patient cardholder must ensure that medical
19 cannabis is stored in such a way that it is inaccessible to members of the
20 cardholder's household, except for a member of the household who is:
21 (a) A medical cannabis caregiver cardholder; and
22 (b) Assisting the medical cannabis patient cardholder with authorized
23 use of medical cannabis.
24 39-9616. LOST OR STOLEN MEDICAL CANNABIS CARD. (1) If a medical
25 cannabis card is lost or stolen, the medical cannabis cardholder must report
26 the lost or stolen card to the department.
27 (2) Upon receiving the report described in subsection (1) of this sec-
28 tion, the department shall designate the medical cannabis card as lost or
29 stolen in the electronic verification system.
30 (3) A medical cannabis pharmacy agent may confiscate a medical cannabis
31 card that is designated as lost or stolen in accordance with subsection (2)
32 of this section if an individual presents the card at the medical cannabis
33 pharmacy.
34 (4) To request a new medical cannabis card, the medical cannabis card-
35 holder described in subsection (1) of this section must:
36 (a) Complete a form as designated by the department; and
37 (b) Pay a fee in an amount set by the department.
38 39-9617. CANNABIS, CANNABIS PRODUCT, OR MEDICAL CANNABIS DEVICE IM-
39 PORTATION AND TRANSPORTATION. (1) The board shall establish rules, subject
40 to legislative approval, for the importation of cannabis, cannabis prod-
41 ucts, and medical cannabis devices into this state, and any person acting
42 according to and in compliance with such rules shall be considered to be
43 acting in compliance with this chapter.
44 (2) The board shall establish rules, subject to legislative approval,
45 for the transportation of cannabis, cannabis products, and medical cannabis
46 devices around this state, and any person acting according to and in compli-
47 ance with such rules shall be considered to be acting in compliance with this
48 chapter.

18
1 (3) The board may establish by rule, subject to legislative approval,
2 requirements for transporting cannabis in an unprocessed form or a medici-
3 nal dosage form, a cannabis product in a medicinal dosage form, or a medical
4 cannabis device to ensure that the cannabis, cannabis product, or medical
5 cannabis device remains safe for human consumption or use.
6 (4) If a person imports or transports cannabis, cannabis products, or
7 medical cannabis devices in a manner that does not comply with the provisions
8 of this section, then the protections of this chapter shall not apply, and
9 such person shall be subject to the provisions of chapter 27, title 37, Idaho
10 Code.
11 39-9618. ENFORCEMENT -- CRIMINAL. (1) Except as provided in this chap-
12 ter, it is unlawful for a medical cannabis cardholder to sell or otherwise
13 give to another medical cannabis cardholder cannabis in a medicinal dosage
14 form, a cannabis product in a medicinal dosage form, a medical cannabis de-
15 vice, or any cannabis residue remaining in or from a medical cannabis device.
16 (2)(a) Except as provided in paragraph (b) of this subsection, a med-
17 ical cannabis cardholder who violates the provisions of subsection (1)
18 of this section is:
19 (i) Guilty of a misdemeanor; and
20 (ii) Subject to a fine of one thousand dollars ($1,000).
21 (b) An individual is not guilty under paragraph (a) of this subsection
22 if the individual is a designated caregiver and gives the product de-
23 scribed in subsection (1) of this section to the medical cannabis card-
24 holder who designated the individual as a designated caregiver.
25 (c) An individual who is guilty of a violation described in paragraph
26 (a) of this subsection is not guilty of a violation of chapter 27, title
27 37, Idaho Code, for the conduct underlying the violation.
28 (3) It is unlawful for a medical cannabis cardholder to sell or other-
29 wise give to a nonmedical cannabis cardholder cannabis in a medicinal dosage
30 form, a cannabis product in a medicinal dosage form, a medical cannabis de-
31 vice, or any cannabis residue remaining in or from a medical cannabis device.
32 A medical cannabis cardholder who violates the provisions of this subsection
33 is subject to:
34 (a) Any applicable penalty under chapter 27, title 37, Idaho Code; and
35 (b) Upon conviction, permanent revocation of the medical cannabis
36 card. Each medical cannabis card issued must include a warning visible
37 on the card that permanent revocation of the card may result from a vi-
38 olation of this subsection.
39 39-9619. REPORT. (1) By January 31 of each year, the board and the de-
40 partment shall report to the senate and house of representatives health and
41 welfare committees on:
42 (a) The number of applications and renewal applications filed for medi-
43 cal cannabis cards;
44 (b) The number of qualifying patients and designated caregivers;
45 (c) The nature of the debilitating medical conditions of the qualifying
46 patients;
47 (d) The age and county of residence of cardholders;
48 (e) The number of medical cannabis cards revoked;

19
1 (f) The number of practitioners providing recommendations for qualify-
2 ing patients;
3 (g) The number of license applications and renewal license applica-
4 tions received;
5 (h) The number of licenses the board has issued in each county;
6 (i) The number of licenses the board has revoked; and
7 (j) The expenses incurred and revenues generated from the medical
8 cannabis program.
9 (2) The board and the department may not include personally identifying
10 information in the report described in this section.
11 39-9620. RULEMAKING -- TRAINING. (1) The board and the department are
12 authorized to promulgate rules, subject to legislative approval, as neces-
13 sary to implement the provisions of this chapter.
14 (2) The board shall, in cooperation with the Idaho state police and
15 other relevant agencies, develop and offer training on the provisions of
16 this chapter, including training for law enforcement personnel.
17 39-9621. IMMUNITIES -- ACTIVITIES NOT PERMITTED -- PENALTIES. (1)
18 Notwithstanding any provision of law to the contrary, a person acting under
19 the authorization of and in compliance with the provisions of this chapter
20 is not subject to prosecution under state law or local ordinance for any au-
21 thorized and compliant conduct.
22 (2) The provisions of this chapter shall not be construed to permit a
23 person to:
24 (a) Operate, navigate, or be in actual physical control of any vehicle,
25 aircraft, railroad train, stationary heavy equipment, or vessel while
26 under the influence of cannabis; or
27 (b) Use cannabis in any public area unless specifically permitted by
28 board rule.
29 (3) A person who commits an act described in subsection (2) of this sec-
30 tion is subject to such penalties as are provided by law.
31 39-9622. PROHIBITIONS. (1) A peace officer may not expend any state or
32 local resources, including the peace officer's time, to:
33 (a) Effect an arrest or seizure of cannabis or conduct any investiga-
34 tion on the sole basis of activity that the peace officer believes to
35 constitute a violation of federal law if the peace officer has reason to
36 believe that the activity is in compliance with this chapter;
37 (b) Enforce a law that restricts an individual's right to acquire, own,
38 or possess a firearm based solely on the individual's possession or use
39 of medical cannabis in accordance with this chapter; or
40 (c) Provide any information or logistical support related to an activ-
41 ity described in paragraph (a) of this subsection to any federal law en-
42 forcement authority or prosecuting entity.
43 (2) A state agency or political subdivision may not take adverse action
44 against a person for providing a professional service to a medical cannabis
45 pharmacy on the sole basis that the service is a violation of federal law.

20
1 39-9623. PROTECTIONS. (1) A person shall not be subject to arrest,
2 prosecution, or penalty in any manner or denied any right or privilege,
3 including without limitation a civil penalty or disciplinary action by a
4 business, occupational, or professional licensing board or bureau, for any
5 act authorized by this chapter.
6 (2) No landlord, school district, public charter school, state insti-
7 tution of higher education, or community college organized pursuant to chap-
8 ter 21, title 33, Idaho Code, may:
9 (a) Refuse to enroll, refuse to lease to, or otherwise penalize a person
10 for any act authorized by this chapter, unless failing to do so would vi-
11 olate federal law or regulation or cause a loss of a monetary or licens-
12 ing-related benefit under federal law or regulation; or
13 (b) Be penalized or denied any benefit under state law or local ordi-
14 nance for enrolling, leasing to, or employing a medical cannabis card-
15 holder.
16 (3) An employer may not:
17 (a) Discriminate against a person in hiring, termination, or any term
18 or condition of employment, or otherwise penalize a person, for any act
19 authorized by this chapter, unless compliance with this paragraph would
20 disqualify the employer from a monetary or licensing-related benefit
21 under federal law or regulation; or
22 (b) Be penalized or denied any benefit under state law or local ordi-
23 nance for employing a medical cannabis cardholder.
24 (4) A person otherwise entitled to custody of, or visitation or parent-
25 ing time with, a minor may not be denied custody or visitation or parenting
26 time solely for conduct allowed under this chapter, nor may there be:
27 (a) A finding or presumption of abuse solely for conduct allowed under
28 this chapter; or
29 (b) A finding or presumption of neglect or child endangerment solely
30 for conduct allowed under this chapter.
31 (5) A person who uses medical cannabis as authorized by this chapter
32 will be afforded all the same rights under state law and local ordinance as
33 the person would be afforded if the person were solely prescribed a pharma-
34 ceutical medication as it pertains to:
35 (a) Any interaction with a person's employer;
36 (b) Drug testing by a person's employer; or
37 (c) Drug testing required by any state law, local ordinance, state
38 agency, or state or local government official.
39 (6) Notwithstanding the provisions of subsection (3) or (5) of this
40 section, no employer is required to allow the ingestion of cannabis in any
41 workplace or to allow any employee to work while under the influence of
42 cannabis. A medical cannabis patient cardholder will not be considered to
43 be under the influence of cannabis solely because of the presence of metabo-
44 lites or components of cannabis that appear in insufficient concentration to
45 cause impairment.
46 39-9624. SEVERABILITY. The provisions of this chapter are hereby de-
47 clared to be severable and if any provision of this chapter or the applica-
48 tion of such provision to any person or circumstance is declared invalid for

21
1 any reason, such declaration shall not affect the validity of the remaining
2 portions of this chapter.
3 SECTION 2. That Section 37-2705, Idaho Code, be, and the same is hereby
4 amended to read as follows:
5 37-2705. SCHEDULE I. (a) The controlled substances listed in this sec-
6 tion are included in schedule I.
7 (b) Any of the following opiates, including their isomers, esters,
8 ethers, salts, and salts of isomers, esters, and ethers, unless specifically
9 excepted, whenever the existence of these isomers, esters, ethers and salts
10 is possible within the specific chemical designation:
11 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip-
12 eridinyl]-N-phenylacetamide);
13 (2) Acetylmethadol;
14 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac-
15 etamide);
16 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacry-
17 lamide);
18 (5) Allylprodine;
19 (6) Alphacetylmethadol (except levo-alphacetylmethadol also known as
20 levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);
21 (7) Alphameprodine;
22 (8) Alphamethadol;
23 (9) Alpha-methylfentanyl;
24 (10) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
25 piperidinyl]-N-phenylpropanamide);
26 (11) Benzethidine;
27 (12) Betacetylmethadol;
28 (13) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperid-
29 inyl]-N-phenylpropanamide);
30 (14) Beta-hydroxythiofentanyl;
31 (15) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-
32 methyl-4-piperidinyl)-N-phenylpropanamide);
33 (16) Betameprodine;
34 (17) Betamethadol;
35 (18) Beta-methyl fentanyl;
36 (19) Beta'-phenyl fentanyl;
37 (20) Betaprodine;
38 (21) Brorphine (1-(1-(1-(4-Bromophenyl)ethyl)piperidin-4-yl)-1,3-
39 dihydro-2H-benzo[D]imidazol-2-one);
40 (22) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1hbenzimida-
41 zol-1-yl)-N,N-diethylethan-1-amine);
42 (23) Clonitazene;
43 (24) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenyl-
44 but-2-enamide);
45 (25) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcy-
46 clopentanecarboxamide);
47 (26) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcy-
48 clopropanecarboxamide);
49 (27) Dextromoramide;

22
1 (28) Diampromide;
2 (29) Diethylthiambutene;
3 (30) Difenoxin;
4 (31) Dimenoxadol;
5 (32) Dimepheptanol;
6 (33) Dimethylthiambutene;
7 (34) Dioxaphetyl butyrate;
8 (35) Dipipanone;
9 (36) Ethylmethylthiambutene;
10 (37) Etodesnitazene; Etazene (2-(2-(4-ethoxybenzyl)-1hbenzimida-
11 zol-1-yl)-N,N-diethylethan-1-amine);
12 (38) Etonitazene;
13 (39) Etoxeridine;
14 (40) Fentanyl-related substances. "Fentanyl-related substances"
15 means any substance not otherwise listed and for which no exemption or
16 approval is in effect under section 505 of the federal food, drug, and
17 cosmetic act, 21 U.S.C. 355, and that is structurally related to fen-
18 tanyl by one (1) or more of the following modifications:
19 i. Replacement of the phenyl portion of the phenethyl group by any
20 monocycle, whether or not further substituted in or on the monocy-
21 cle;
22 ii. Substitution in or on the phenethyl group with alkyl, alkenyl,
23 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
24 iii. Substitution in or on the piperidine ring with alkyl,
25 alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino,
26 or nitro groups;
27 iv. Replacement of the aniline ring with any aromatic monocycle,
28 whether or not further substituted in or on the aromatic monocy-
29 cle; and/or
30 v. Replacement of the N-propionyl group by another acyl group;
31 (41) Fentanyl carabamate;
32 (42) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1h-ben-
33 zimidazol-1-yl)ethan-1-amine);
34 (43) 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
35 phenethylpiperidin-4-yl)isobutyramide);
36 (44) 2'-fluoro ortho-fluorofentanyl;
37 (45) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfu-
38 ran-2-carboxamide);
39 (46) Furethidine;
40 (47) Hydroxypethidine;
41 (48) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
42 phenylisobutyramide);
43 (49) Isotonitazene (N,N-diethyl-2-(2-(4isopropoxybenzyl)-5-ni-
44 tro-1h-benzimidazol-1-yl)ethan-1-amine);
45 (50) Ketobemidone;
46 (51) Levomoramide;
47 (52) Levophenacylmorphan;
48 (53) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-
49 yl)-N-phenylacetamide);
50 (54) 4'-methyl acetyl fentanyl;

23
1 (55) 3-Methylfentanyl;
2 (56) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-pip-
3 eridinyl]-N-phenylpropanamide);
4 (57) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1h-benzim-
5 idazol-1-yl)ethan-1-amine);
6 (58) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-
7 1hbenzimidazol-1-yl)ethan-1-amine);
8 (59) Morpheridine;
9 (60) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
10 (61) MT-45 (1-cyclohexyl-4- (1,2-diphenylethyl)piperazine);
11 (62) N-(4-chlorophenyl)-N-(1-phenethylpiperdin-4-yl)Isobutyramide
12 (para-chloroisobutyrl fentanyl);
13 (63) Noracymethadol;
14 (64) Norlevorphanol;
15 (65) Normethadone;
16 (66) Norpipanone;
17 (67) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1-(2-
18 (pyrrolidin-1-yl)ethyl)1hbenzimidazole);
19 (68) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethyl-
20 piperidin-4-yl)acetamide);
21 (69) Ortho-fluoroacryl fentanyl;
22 (70) Ortho-fluorobutyrl fentanyl;
23 (71) Ortho-fluorofentanyl;
24 (72) Ortho-fluoroisobutyryl fentanyl;
25 (73) Ortho-methyl acetylfentanyl;
26 (74) Ortho-methyl methoxyacetyl fentanyl;
27 (75) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-
28 phenethylpiperidin-4-yl) isobutyramide);
29 (76) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
30 phenethylpiperidin-4-yl) butyramide);
31 (77) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
32 piperidinyl] propanamide);
33 (78) Para-fluoro furanyl fentanyl;
34 (79) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-
35 phenethylpiperidin-4-yl) butyramide);
36 (80) Para-methylfentanyl;
37 (81) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
38 (82) Phenadoxone;
39 (83) Phenampromide;
40 (84) Phenomorphan;
41 (85) Phenoperidine;
42 (86) Phenyl fentanyl;
43 (87) Piritramide;
44 (88) Proheptazine;
45 (89) Properidine;
46 (90) Propiram;
47 (91) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1h-
48 benzimidazol-1-yl)ethan-1-amine);
49 (92) Racemoramide;

24
1 (93) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidine-4-yl)-N-
2 phenyltetrahydrofuran-2-carboxamide);
3 (94) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
4 propanamide);
5 (95) Tilidine;
6 (96) Trimeperidine;
7 (97) u-47700 (3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
8 methylbenzamide);
9 (98) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyl-
10 pentanamide);
11 (99) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piper-
12 azin-1-yl]-1-phenylpropan-2-ol).
13 (c) Any of the following opium derivatives, their salts, isomers and
14 salts of isomers, unless specifically excepted, whenever the existence of
15 these salts, isomers and salts of isomers is possible within the specific
16 chemical designation:
17 (1) Acetorphine;
18 (2) Acetyldihydrocodeine;
19 (3) Benzylmorphine;
20 (4) Codeine methylbromide;
21 (5) Codeine-N-Oxide;
22 (6) Cyprenorphine;
23 (7) Desomorphine;
24 (8) Dihydromorphine;
25 (9) Drotebanol;
26 (10) Etorphine (except hydrochloride salt);
27 (11) Heroin;
28 (12) Hydromorphinol;
29 (13) Methyldesorphine;
30 (14) Methyldihydromorphine;
31 (15) Morphine methylbromide;
32 (16) Morphine methylsulfonate;
33 (17) Morphine-N-Oxide;
34 (18) Myrophine;
35 (19) Nicocodeine;
36 (20) Nicomorphine;
37 (21) Normorphine;
38 (22) Pholcodine;
39 (23) Thebacon.
40 (d) Hallucinogenic substances. Any material, compound, mixture or
41 preparation that contains any quantity of the following hallucinogenic
42 substances, their salts, isomers and salts of isomers, unless specifically
43 excepted, whenever the existence of these salts, isomers, and salts of iso-
44 mers is possible within the specific chemical designation (for purposes of
45 this subsection only, the term "isomer" includes the optical, position and
46 geometric isomers):
47 (1) Dimethoxyphenethylamine, or any compound not specifically
48 excepted or listed in another schedule that can be formed from
49 dimethoxyphenethylamine by replacement of one (1) or more hydrogen
50 atoms with another atom(s), functional group(s) or substructure(s)

25
1 including, but not limited to, compounds such as DOB, DOC, 2C-B,
2 25B-NBOMe;
3 (2) Methoxyamphetamine or any compound not specifically excepted or
4 listed in another schedule that can be formed from methoxyamphetamine
5 by replacement of one (1) or more hydrogen atoms with another atom(s),
6 functional group(s) or substructure(s) including, but not limited to,
7 compounds such as PMA and DOM;
8 (3) 5-methoxy-3,4-methylenedioxy-amphetamine;
9 (4) 5-methoxy-N,N-diisopropyltryptamine;
10 (5) Amphetamine or methamphetamine with a halogen substitution on the
11 benzyl ring, including compounds such as fluorinated amphetamine and
12 fluorinated methamphetamine;
13 (6) 3,4-methylenedioxy amphetamine;
14 (7) 3,4-methylenedioxymethamphetamine (MDMA);
15 (8) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-
16 hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-
17 hyl MDA, MDE, MDEA);
18 (9) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-
19 roxy-alpha-methyl-3,4(methylenedioxy) phenethylamine, and N-hyd-
20 roxy MDA);
21 (10) 3,4,5-trimethoxy amphetamine;
22 (11) 5-methoxy-N,N-dimethyltryptamine (also known as 5-methoxy-3-2[2-
23 (dimethylamino)ethyl]indole and 5-MeO-DMT);
24 (12) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-
25 inobutyl) indole);
26 (13) Alpha-methyltryptamine;
27 (14) Bufotenine;
28 (15) Diethyltryptamine (DET);
29 (16) Dimethyltryptamine (DMT);
30 (17) Ibogaine;
31 (18) Lysergic acid diethylamide;
32 (19) Marihuana;
33 (20) (19) Mescaline;
34 (21) (20) Methoxetamine;
35 (22) (21) Parahexyl;
36 (23) (22) Peyote;
37 (24) (23) N-ethyl-3-piperidyl benzilate;
38 (25) (24) N-methyl-3-piperidyl benzilate;
39 (26) (25) Para-methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-
40 methylpropan-2-amine;
41 (27) (26) Psilocybin;
42 (28) (27) Psilocyn;
43 (29) Tetrahydrocannabinols or synthetic equivalents of the substances
44 contained in the plant, or in the resinous extractives of Cannabis, sp.
45 and/or synthetic substances, derivatives, and their isomers with simi-
46 lar chemical structure such as the following:
47 i. Tetrahydrocannabinols, except for the permitted amount of
48 tetrahydrocannabinol found in industrial hemp, or nabiximols in a
49 drug product approved by the United States food and drug adminis-
50 tration:

26
1 a. ∆ 1 cis or trans tetrahydrocannabinol, and their opti-
2 cal isomers, excluding dronabinol in sesame oil and encapsu-
3 lated in either a soft gelatin capsule or in an oral solution
4 in a drug product approved by the U.S. Food and Drug Adminis-
5 tration.
6 b. ∆ 6 cis or trans tetrahydrocannabinol, and their optical
7 isomers.
8 c. ∆ 3,4 cis or trans tetrahydrocannabinol, and its optical
9 isomers. (Since nomenclature of these substances is not in-
10 ternationally standardized, compounds of these structures,
11 regardless of numerical designation of atomic positions are
12 covered.)
13 d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methy-
14 loctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-
15 1-o1)], also known as 6aR-trans-3-(1,1-dimethylhep-
16 tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
17 dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric
18 isomers (HU211 or dexanabinol).
19 ii. The following synthetic drugs:
20 a. Any compound structurally derived from (1H-indole-3-
21 yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-
22 dole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or
23 (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl), methyl
24 or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobu-
25 tan-2-yl) carboxamide by substitution at the nitrogen atoms
26 of the indole ring or carboxamide to any extent, whether or
27 not further substituted in or on the indole ring to any ex-
28 tent, whether or not substituted to any extent in or on the
29 cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the
30 ring may include, but is not limited to, heteroatoms such as
31 nitrogen, sulfur and oxygen).
32 b. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluo-
33 ropentyl)-1 H-indazole-3-carboxamide (5F-AB-PINACA).
34 c. 1-(1.3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
35 (N-ethylpentylone, ephylone).
36 d. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-inda-
37 zole-3-carboxamide (4-cn-cumyl-BUTINACA).
38 e. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3carboxam-
39 ido)-3,3-dimethylbutanoate * (5F-EDMB-PINACA).
40 f. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3tetram-
41 ethylcyclopropyl)methanone ( FUB-144).
42 g. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-inda-
43 zole-3-carboxamide (5f-cumyl-pinaca; SGT-25).
44 h. (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
45 H-pyrrolo[2.3-B]pyridine-3-carboxamide(5fcumyl-P7AICA).
46 i. FUB-AMB, MMB- FUBINACA (Methyl 2-(1-(4-fluoroben-
47 zyl)-1H-indazole-3-carboxamido)-3-methylbutanoate.
48 j. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
49 ido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).

27
1 k. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
2 ido)-3,3-dimethylbutanoate (MDMB-CHMICA).
3 l. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxam-
4 ido-3,3-dimethylbutanoate (MDMB-FUBINACA).
5 m. Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxam-
6 ido)-3,3-dimethylbutanoate (5F-MDMBPICA).
7 n. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
8 ido)-3,3-dimethylbutanoate (5F-ADB, 5FMDMB-PINACA).
9 o. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
10 ido)-3-methylbutanoate (5FAMB).
11 p. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluo-
12 robenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).
13 q. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
14 carboxamide (FUB-AKB48; FUB-APINACA).
15 r. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
16 carboxamide (5F-APINACA, 5F-AKB48).
17 s. N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(Cyclohexyl-
18 methyl)-1H-indazole-3-carboxamide (AB-CHMINACA).
19 t. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-car-
20 boxylate (NM2201; CBL2201).
21 u. Any compound structurally derived from 3-(1-naph-
22 thoyl)pyrrole by substitution at the nitrogen atom of the
23 pyrrole ring to any extent, whether or not further sub-
24 stituted in the pyrrole ring to any extent, whether or not
25 substituted in the naphthyl ring to any extent.
26 v. Any compound structurally derived from 1-(1-naphthyl-
27 methyl)indene by substitution at the 3-position of the in-
28 dene ring to any extent, whether or not further substituted
29 in the indene ring to any extent, whether or not substituted
30 in the naphthyl ring to any extent.
31 w. Any compound structurally derived from 3-pheny-
32 lacetylindole by substitution at the nitrogen atom of the
33 indole ring to any extent, whether or not further substi-
34 tuted in the indole ring to any extent, whether or not sub-
35 stituted in the phenyl ring to any extent.
36 x. Any compound structurally derived from 2-(3-hydroxycy-
37 clohexyl)phenol by substitution at the 5-position of the
38 phenolic ring to any extent, whether or not substituted in
39 the cyclohexyl ring to any extent.
40 y. Any compound structurally derived from 3-(benzoyl)in-
41 dole structure with substitution at the nitrogen atom of
42 the indole ring to any extent, whether or not further sub-
43 stituted in the indole ring to any extent and whether or not
44 substituted in the phenyl ring to any extent.
45 z. [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrol-
46 o[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone
47 (WIN-55,212-2).
48 aa. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-
49 243).

28
1 bb. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-
2 5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahy-
3 drophenanthridin-1-yl]acetate (CP 50,5561).
4 (30) (28) Ethylamine analog of phencyclidine: N-ethyl-1-phenylcy-
5 clohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcy-
6 clohexyl) ethylamine, cyclohexamine, PCE;
7 (31) (29) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohex-
8 yl) -pyrrolidine, PCPy, PHP;
9 (32) (30) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cy-
10 clohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;
11 (33) (31) Thiofuranyl fentanyl;
12 (34) (32) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name:
13 TCPy;
14 (35) (33) Spores or mycelium capable of producing mushrooms that con-
15 tain psilocybin or psilocin.
16 (e) Unless specifically excepted or unless listed in another schedule,
17 any material, compound, mixture or preparation which contains any quantity
18 of the following substances having a depressant effect on the central ner-
19 vous system, including its salts, isomers, and salts of isomers whenever the
20 existence of such salts, isomers, and salts of isomers is possible within the
21 specific chemical designation:
22 (1) Gamma hydroxybutyric acid (some other names include GHB; gam-
23 ma-hydroxybutyrate, 4-hydroxybutyrate; 4-hyroxybutanoic acid; sod-
24 ium oxybate; sodium oxybutyrate);
25 (2) Flunitrazepam (also known as R2, Rohypnol);
26 (3) Mecloqualone;
27 (4) Methaqualone.
28 (f) Stimulants. Unless specifically excepted or unless listed in an-
29 other schedule, any material, compound, mixture, or preparation which con-
30 tains any quantity of the following substances having a stimulant effect on
31 the central nervous system, including its salts, isomers, and salts of iso-
32 mers:
33 (1) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-
34 yl)amino]heptanoic acid);
35 (2) Aminorex (some other names: aminoxaphen, 2-amino-5-phenyl-2-ox-
36 azoline, or 4,5-dihydro-5-phenyl-2-oxazolamine), 4,4'-dimethylam-
37 inorex (4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazo-
38 lamine) or (4,5-dihydro-5-phenyl-2-oxazolamine);
39 (3) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alp-
40 ha-aminopropiophenone, 2-aminopropiophenone and norephedrone);
41 (4) Substituted cathinones. Any compound, except bupropion or com-
42 pounds listed under a different schedule, structurally derived from
43 2-aminopropan-1-one by substitution at the 1-position with either
44 phenyl, naphthyl or thiophene ring systems, whether or not the compound
45 is further modified in any of the following ways:
46 i. By substitution in the ring system to any extent with alkyl,
47 alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide sub-
48 stituents, whether or not further substituted in the ring system
49 by one (1) or more other univalent substituents;

29
1 ii. By substitution at the 3-position with an acyclic alkyl sub-
2 stituent;
3 iii. By substitution at the 2-amino nitrogen atom with alkyl,
4 dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the
5 2-amino nitrogen atom in a cyclic structure.
6 (5) Alpha-pyrrolidinoheptaphenone* (PV8);
7 (6) Alpha-pyrrolidinohexanophenone* (A-PHP);
8 (7) 4-chloro-alpha-pyrrolidinovalerophenone* (4chloro-a-pvp);
9 (8) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one);
10 (9) Fenethylline;
11 (10) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadia-
12 zol-3-ium-5-yl)carbamimidate);
13 (11) Methcathinone (some other names: 2-(methyl-amino)-propioph-
14 enone, alpha-(methylamino)-propiophenone, N-methylcathinone, AL-
15 464, AL-422, AL-463 and UR1423);
16 (12) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine);
17 (13) (+/-)cis-4-methylaminorex [(+/-)cis-4,5-dihydro-4-meth-
18 yl-5-phenyl-2-oxazolamine];
19 (14) 4-methyl-alpha-ethylaminopentiophenone* (4-MEAP);
20 (15) 4'-methyl-alpha-pyrrolidinohexiophenone* (MPHP);
21 (16) N-benzylpiperazine (also known as: BZP, 1-benzylpiperazine);
22 (17) N-ethylamphetamine;
23 (18) N-ethylhexedrone*;
24 (19) N,N-dimethylamphetamine (also known as: N,N-alpha-trimethyl-
25 benzeneethanamine).
26 SECTION 3. That Section 37-2707, Idaho Code, be, and the same is hereby
27 amended to read as follows:
28 37-2707. SCHEDULE II. (a) Schedule II shall consist of the drugs and
29 other substances, by whatever official name, common or usual name, chemical
30 name, or brand name designated, listed in this section.
31 (b) Substances, vegetable origin or chemical synthesis. Unless
32 specifically excepted or unless listed in another schedule, any of the fol-
33 lowing substances whether produced directly or indirectly by extraction
34 from substances of vegetable origin, or independently by means of chemical
35 synthesis, or by a combination of extraction and chemical synthesis:
36 (1) Opium and opiate, and any salt, compound, derivative, or prepa-
37 ration of opium or opiate, excluding apomorphine, dextrorphan, nal-
38 buphine, nalmefene, naloxone, naltrexone and their respective salts,
39 but including the following:
40 1. Raw opium;
41 2. Opium extracts;
42 3. Opium fluid extracts;
43 4. Powdered opium;
44 5. Granulated opium;
45 6. Tincture of opium;
46 7. Codeine;
47 8. Dihydroetorphine;
48 9. Diprenorphine;
49 10. Ethylmorphine;

30
1 11. Etorphine hydrochloride;
2 12. Hydrocodone;
3 13. Hydromorphone;
4 14. Metopon;
5 15. Morphine;
6 16. Oripavine;
7 17. Oxycodone;
8 18. Oxymorphone;
9 19. Tapentadol;
10 20. Thebaine.
11 (2) Any salt, compound, derivative, or preparation thereof which is
12 chemically equivalent or identical with any of the substances referred
13 to in paragraph (1) of this subsection, except that these substances
14 shall not include the isoquinoline alkaloids of opium.
15 (3) Opium poppy and poppy straw.
16 (4) Coca leaves and any salt, compound, derivative, or preparation
17 of coca leaves, and any salt, compound, derivative, or preparation
18 thereof which is chemically equivalent or identical with any of these
19 substances, but shall not include the following:
20 1. Decocainized coca leaves or extractions of coca leaves, which
21 extractions do not contain cocaine; or ecgonine; or
22 2. [123I]ioflupane.
23 (5) Benzoylecgonine.
24 (6) Methylbenzoylecgonine (Cocaine - its salts, optical isomers, and
25 salts of optical isomers).
26 (7) Concentrate of poppy straw (the crude extract of poppy straw in liq-
27 uid, solid or powder form that contains the phenanthrine alkaloids of
28 the opium poppy).
29 (c) Any of the following opiates, including their isomers, esters,
30 ethers, salts, and salts of isomers, whenever the existence of these iso-
31 mers, esters, ethers and salts is possible within the specific chemical
32 designation, unless specifically excepted or unless listed in another
33 schedule:
34 (1) Alfentanil;
35 (2) Alphaprodine;
36 (3) Anileridine;
37 (4) Bezitramide;
38 (5) Bulk Dextropropoxyphene (nondosage forms);
39 (6) Carfentanil;
40 (7) Dihydrocodeine;
41 (8) Diphenoxylate;
42 (9) Fentanyl;
43 (10) Isomethadone;
44 (11) Levo-alphacetylmethadol (also known as levo-alpha-acetylmet-
45 hadol, levomethadyl acetate, LAAM);
46 (12) Levomethorphan;
47 (13) Levorphanol;
48 (14) Metazocine;
49 (15) Methadone;

31
1 (16) Methadone -- Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl
2 butane;
3 (17) Moramide -- Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl
4 propane-carboxylic acid;
5 (18) Norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide);
6 (19) Oliceridine;
7 (20) Pethidine (meperidine);
8 (21) Pethidine -- Intermediate -- A, 4-cyano-1-methyl-4-phenyl-
9 piperidine;
10 (22) Pethidine -- Intermediate -- B, ethyl-4-phenylpiperidine-4-car-
11 boxylate;
12 (23) Pethidine -- Intermediate -- C, 1-methyl-4-phenylpiperid-
13 ine-4-carboxylic acid;
14 (24) Phenazocine;
15 (25) Piminodine;
16 (26) Racemethorphan;
17 (27) Racemorphan;
18 (28) Remifentanil;
19 (29) Sufentanil.
20 (d) Stimulants. Unless specifically excepted or unless listed in an-
21 other schedule, any material, compound, mixture, or preparation which con-
22 tains any quantity of the following substances having a stimulant effect on
23 the central nervous system:
24 (1) Amphetamine, its salts, optical isomers, and salts of its optical
25 isomers;
26 (2) Lisdexamfetamine;
27 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
28 (4) Phenmetrazine and its salts;
29 (5) Methylphenidate.
30 (e) Depressants. Unless specifically excepted or unless listed in an-
31 other schedule, any material, compound, mixture, or preparation which con-
32 tains any quantity of the following substances having a depressant effect on
33 the central nervous system, including its salts, isomers, and salts of iso-
34 mers, whenever the existence of such salts, isomers, and salts of isomers is
35 possible within the specific chemical designation:
36 (1) Amobarbital;
37 (2) Glutethimide;
38 (3) Pentobarbital;
39 (4) Phencyclidine;
40 (5) Secobarbital.
41 (f) Hallucinogenic substances.
42 (1) Nabilone ............................ (another name for nabilone:
43 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hy-
44 droxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one) (21 CFR 1308.12 (f)).
45 (g) Immediate precursors. Unless specifically excepted or unless
46 listed in another schedule, any material, compound, mixture, or preparation
47 which contains any quantity of the following substances:
48 (1) Immediate precursor to amphetamine and methamphetamine:
49 (a) Anthranilic acid;
50 (b) Ephedrine;

32
1 (c) Lead acetate;
2 (d) Methylamine;
3 (e) Methyl formamide;
4 (f) N-methylephedrine;
5 (g) Phenylacetic acid;
6 (h) Phenylacetone;
7 (i) Phenylpropanolamine;
8 (j) Pseudoephedrine.
9 Except that any combination or compound containing ephedrine, or any of
10 its salts and isomers, or phenylpropanolamine or its salts and isomers,
11 or pseudoephedrine, or any of its salts and isomers which is prepared
12 for dispensing or over-the-counter distribution is not a controlled
13 substance for the purpose of this section, unless such substance is pos-
14 sessed, delivered, or possessed with intent to deliver to another with
15 the intent to manufacture methamphetamine, amphetamine or any other
16 controlled substance in violation of section 37-2732, Idaho Code. For
17 purposes of this provision, the requirements of the uniform controlled
18 substances act shall not apply to a manufacturer, wholesaler or re-
19 tailer of over-the-counter products containing the listed substances
20 unless such person possesses, delivers, or possesses with intent to
21 deliver to another the over-the-counter product with intent to manufac-
22 ture a controlled substance.
23 (2) Immediate precursors to phencyclidine (PCP):
24 (a) 1-phenylcyclohexylamine;
25 (b) 1-piperidinocyclohexanecarbonitrile (PCC).
26 (3) Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-piperi-
27 dine (ANPP).
28 (h) Marijuana.
29 (i) Tetrahydrocannabinols or synthetic equivalents of the substances
30 contained in the plant, or in the resinous extractives of Cannabis, sp.
31 and/or synthetic substances, derivatives, and their isomers with similar
32 chemical structure such as the following:
33 (1) Tetrahydrocannabinols, except for the permitted amount of tetrahy-
34 drocannabinol found in industrial hemp, or nabiximols in a drug product
35 approved by the United States food and drug administration:
36 (a) ∆ 1 cis or trans tetrahydrocannabinol, and their optical iso-
37 mers, excluding dronabinol in sesame oil and encapsulated in ei-
38 ther a soft gelatin capsule or in an oral solution in a drug product
39 approved by the U.S. Food and Drug Administration.
40 (b) ∆ 6 cis or trans tetrahydrocannabinol, and their optical iso-
41 mers.
42 (c) ∆ 3,4 cis or trans tetrahydrocannabinol, and its optical iso-
43 mers. (Since nomenclature of these substances is not internation-
44 ally standardized, compounds of these structures, regardless of
45 numerical designation of atomic positions are covered.)
46 (d) [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methyloc-
47 tan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-o1)], also
48 known as 6aR-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahy-
49 dro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol
50 (HU-210) and its geometric isomers (HU211 or dexanabinol).

33
1 (2) The following synthetic drugs:
2 (a) Any compound structurally derived from (1H-indole-3-yl)(cy-
3 cloalkyl, cycloalkenyl, aryl)methanone, or (1H-indole-3-yl)(cy-
4 cloalkyl, cycloalkenyl, aryl)methane, or (1H-indole-3-yl)(cy-
5 cloalkyl, cycloalkenyl, aryl), methyl or dimethyl butanoate,
6 amino-methyl (or dimethyl)-1-oxobutan-2-yl) carboxamide by sub-
7 stitution at the nitrogen atoms of the indole ring or carboxamide
8 to any extent, whether or not further substituted in or on the in-
9 dole ring to any extent, whether or not substituted to any extent
10 in or on the cycloalkyl, cycloalkenyl, aryl ring(s) (substitution
11 in the ring may include, but is not limited to, heteroatoms such as
12 nitrogen, sulfur and oxygen).
13 (b) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
14 H-indazole-3-carboxamide (5F-AB-PINACA).
15 (c) 1-(1.3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
16 (N-ethylpentylone, ephylone).
17 (d) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-
18 carboxamide (4-cn-cumyl-BUTINACA).
19 (e) Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3carboxamido)-
20 3,3-dimethylbutanoate * (5F-EDMB-PINACA).
21 (f) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3tetramethylcy-
22 clopropyl)methanone ( FUB-144).
23 (g) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-inda-
24 zole-3-carboxamide (5f-cumyl-pinaca; SGT-25).
25 (h) (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
26 H-pyrrolo[2.3-B]pyridine-3-carboxamide(5fcumyl-P7AICA).
27 (i) FUB-AMB, MMB- FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-in-
28 dazole-3-carboxamido)-3-methylbutanoate.
29 (j) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
30 ido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).
31 (k) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
32 ido)-3,3-dimethylbutanoate (MDMB-CHMICA).
33 (l) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxam-
34 ido-3,3-dimethylbutanoate (MDMB-FUBINACA).
35 (m) Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-
36 3,3-dimethylbutanoate (5F-MDMBPICA).
37 (n) Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
38 ido)-3,3-dimethylbutanoate (5F-ADB, 5FMDMB-PINACA).
39 (o) Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
40 ido)-3-methylbutanoate (5FAMB).
41 (p) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluoroben-
42 zyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).
43 (q) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-car-
44 boxamide (FUB-AKB48; FUB-APINACA).
45 (r) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-car-
46 boxamide (5F-APINACA, 5F-AKB48).
47 (s) N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(Cyclohexylmethyl)-
48 1H-indazole-3-carboxamide (AB-CHMINACA).
49 (t) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxy-
50 late (NM2201; CBL2201).

34
1 (u) Any compound structurally derived from 3-(1-naphthoyl)pyr-
2 role by substitution at the nitrogen atom of the pyrrole ring to
3 any extent, whether or not further substituted in the pyrrole ring
4 to any extent, whether or not substituted in the naphthyl ring to
5 any extent.
6 (v) Any compound structurally derived from 1-(1-naphthyl-
7 methyl)indene by substitution at the 3-position of the indene ring
8 to any extent, whether or not further substituted in the indene
9 ring to any extent, whether or not substituted in the naphthyl ring
10 to any extent.
11 (w) Any compound structurally derived from 3-phenylacetylindole
12 by substitution at the nitrogen atom of the indole ring to any ex-
13 tent, whether or not further substituted in the indole ring to any
14 extent, whether or not substituted in the phenyl ring to any ex-
15 tent.
16 (x) Any compound structurally derived from 2-(3-hydroxycyclo-
17 hexyl)phenol by substitution at the 5-position of the phenolic
18 ring to any extent, whether or not substituted in the cyclohexyl
19 ring to any extent.
20 (y) Any compound structurally derived from 3-(benzoyl)indole
21 structure with substitution at the nitrogen atom of the indole
22 ring to any extent, whether or not further substituted in the
23 indole ring to any extent and whether or not substituted in the
24 phenyl ring to any extent.
25 (z) [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrro-
26 lo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone
27 (WIN-55,212-2).
28 (aa) 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-243).
29 (bb) [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-5-
30 phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenan-
31 thridin-1-yl]acetate (CP 50,5561).
32 SECTION 4. That Section 37-2732, Idaho Code, be, and the same is hereby
33 amended to read as follows:
34 37-2732. PROHIBITED ACTS A -- PENALTIES. (a) Except as authorized by
35 this chapter or chapter 96, title 39, Idaho Code, it is unlawful for any per-
36 son to manufacture or deliver, or possess with intent to manufacture or de-
37 liver, a controlled substance.
38 (1) Any person who violates this subsection with respect to:
39 (A) A controlled substance classified in schedule I which is a
40 narcotic drug or a controlled substance classified in schedule II,
41 except as provided for in section 37-2732B(a)(3), Idaho Code, is
42 guilty of a felony and upon conviction may be imprisoned for a term
43 of years not to exceed life imprisonment, or fined not more than
44 twenty-five thousand dollars ($25,000), or both;
45 (B) Any other controlled substance which is a nonnarcotic drug
46 classified in schedule I, or a controlled substance classified in
47 schedule III, is guilty of a felony and upon conviction may be im-
48 prisoned for not more than five (5) years, fined not more than fif-
49 teen thousand dollars ($15,000), or both;

35
1 (C) A substance classified in schedule IV is guilty of a felony
2 and upon conviction may be imprisoned for not more than three (3)
3 years, fined not more than ten thousand dollars ($10,000), or
4 both;
5 (D) A substance classified in schedules V and VI is guilty of a
6 misdemeanor and upon conviction may be imprisoned for not more
7 than one (1) year, fined not more than five thousand dollars
8 ($5,000), or both.
9 (b) Except as authorized by this chapter, it is unlawful for any per-
10 son to create, deliver, or possess with intent to deliver, a counterfeit sub-
11 stance.
12 (1) Any person who violates this subsection with respect to:
13 (A) A counterfeit substance classified in schedule I which is a
14 narcotic drug, or a counterfeit substance classified in schedule
15 II, is guilty of a felony and upon conviction may be imprisoned for
16 not more than fifteen (15) years, fined not more than twenty-five
17 thousand dollars ($25,000), or both;
18 (B) Any other counterfeit substance classified in schedule I
19 which is a nonnarcotic drug contained in schedule I or a counter-
20 feit substance contained in schedule III is guilty of a felony and
21 upon conviction may be imprisoned for not more than five (5) years,
22 fined not more than fifteen thousand dollars ($15,000), or both;
23 (C) A counterfeit substance classified in schedule IV is guilty
24 of a felony and upon conviction may be imprisoned for not more
25 than three (3) years, fined not more than ten thousand dollars
26 ($10,000), or both;
27 (D) A counterfeit substance classified in schedules V and VI or
28 a noncontrolled counterfeit substance is guilty of a misdemeanor
29 and upon conviction may be imprisoned for not more than one (1)
30 year, fined not more than five thousand dollars ($5,000), or both.
31 (c) It is unlawful for any person to possess a controlled substance
32 unless the substance was obtained directly from, or pursuant to, a valid
33 prescription or order of a practitioner while acting in the course of his
34 professional practice, or except as otherwise authorized by this chapter or
35 chapter 96, title 39, Idaho Code.
36 (1) Any person who violates this subsection and has in his possession
37 a controlled substance classified in schedule I which is a narcotic
38 drug or a controlled substance classified in schedule II is guilty of
39 a felony and upon conviction may be imprisoned for not more than seven
40 (7) years, or fined not more than fifteen thousand dollars ($15,000), or
41 both.
42 (2) Any person who violates this subsection and has in his possession
43 lysergic acid diethylamide is guilty of a felony and upon conviction may
44 be imprisoned for not more than three (3) years, or fined not more than
45 five thousand dollars ($5,000), or both.
46 (3) Any person who violates this subsection and has in his possession a
47 controlled substance which is a nonnarcotic drug classified in schedule
48 I except lysergic acid diethylamide, or a controlled substance classi-
49 fied in schedules III, IV, V and VI is guilty of a misdemeanor and upon

36
1 conviction thereof may be imprisoned for not more than one (1) year, or
2 fined not more than one thousand dollars ($1,000), or both.
3 (d) It shall be unlawful for any person to be present at or on premises
4 of any place where he knows illegal controlled substances are being manufac-
5 tured or cultivated, or are being held for distribution, transportation, de-
6 livery, administration, use, or to be given away. A violation of this sec-
7 tion shall deem those persons guilty of a misdemeanor and upon conviction
8 shall be punished by a fine of not more than three hundred dollars ($300) and
9 not more than ninety (90) days in the county jail, or both.
10 (e) If any person is found to possess marijuana, which for the purposes
11 of this subsection shall be restricted to all parts of the plants of the
12 genus Cannabis, including the extract or any preparation of cannabis which
13 contains tetrahydrocannabinol, in an amount greater than three (3) ounces
14 net weight, it shall be a felony and upon conviction may be imprisoned for
15 not more than five (5) years, or fined not more than ten thousand dollars
16 ($10,000), or both. The provisions of this subsection do not apply to a per-
17 son acting according to and in compliance with the provisions of chapter 96,
18 title 39, Idaho Code.
19 (f) If two (2) or more persons conspire to commit any offense defined in
20 this act, said persons shall be punished by a fine or imprisonment, or both,
21 which may not exceed the maximum punishment prescribed for the offense, the
22 commission of which was the object of the conspiracy.
23 (g)(1) It is unlawful for any person to manufacture or distribute a
24 "simulated controlled substance," or to possess with intent to distrib-
25 ute a "simulated controlled substance." Any person who violates this
26 subsection shall, upon conviction, be guilty of a misdemeanor and upon
27 conviction thereof shall be punished by a fine of not more than one thou-
28 sand dollars ($1,000) and not more than one (1) year in the county jail,
29 or both.
30 (2) It is unlawful for any person to possess a "simulated controlled
31 substance." Any person who violates this subsection shall, upon convic-
32 tion, be guilty of a misdemeanor and upon conviction thereof shall be
33 punished by a fine of not more than three hundred dollars ($300) and not
34 more than six (6) months in the county jail, or both.
35 (h) It is unlawful for any person to cause to be placed in any newspaper,
36 magazine, handbill, or other publication, or to post or distribute in any
37 public place, any advertisement or solicitation offering for sale simulated
38 controlled substances. Any person who violates this subsection is guilty of
39 a misdemeanor and shall be punished in the same manner as prescribed in sub-
40 section (g) of this section.
41 (i) No civil or criminal liability shall be imposed by virtue of this
42 chapter on any person registered under the uniform controlled substances
43 act who manufactures, distributes, or possesses an imitation controlled
44 substance for use as a placebo or other use by a registered practitioner, as
45 defined in section 37-2701(bb), Idaho Code, in the course of professional
46 practice or research.
47 (j) No prosecution under this chapter shall be dismissed solely by rea-
48 son of the fact that the dosage units were contained in a bottle or other con-
49 tainer with a label accurately describing the ingredients of the imitation

37
1 controlled substance dosage units. The good faith of the defendant shall be
2 an issue of fact for the trier of fact.
3 (k) Upon conviction of a felony or misdemeanor violation under this
4 chapter or upon conviction of a felony pursuant to the racketeering act,
5 section 18-7804, Idaho Code, or the money laundering and illegal investment
6 provisions of section 18-8201, Idaho Code, the court may order restitution
7 for costs incurred by law enforcement agencies in investigating the viola-
8 tion. Law enforcement agencies shall include, but not be limited to, the
9 Idaho state police, county and city law enforcement agencies, the office
10 of the attorney general and county and city prosecuting attorney offices.
11 Costs shall include, but not be limited to, those incurred for the purchase
12 of evidence, travel and per diem for law enforcement officers and witnesses
13 throughout the course of the investigation, hearings and trials, and any
14 other investigative or prosecution expenses actually incurred, including
15 regular salaries of employees. In the case of reimbursement to the Idaho
16 state police, those moneys shall be paid to the Idaho state police for
17 deposit into the drug and driving while under the influence enforcement
18 donation fund created in section 57-816, Idaho Code. In the case of reim-
19 bursement to the office of the attorney general, those moneys shall be paid
20 to the general fund. A conviction for the purposes of this section means that
21 the person has pled guilty or has been found guilty, notwithstanding the form
22 of the judgment(s) or withheld judgment(s).
23 SECTION 5. That Section 37-2732B, Idaho Code, be, and the same is hereby
24 amended to read as follows:
25 37-2732B. TRAFFICKING -- MANDATORY SENTENCES. (a) Except as autho-
26 rized in this chapter or chapter 96, title 39, Idaho Code, and notwithstand-
27 ing the provisions of section 37-2732, Idaho Code:
28 (1) Any person who knowingly manufactures, delivers, or brings into
29 this state, or who is knowingly in actual or constructive possession
30 of, one (1) pound of marijuana or more, or twenty-five (25) marijuana
31 plants or more, as defined in section 37-2701, Idaho Code, is guilty of
32 a felony, which felony shall be known as "trafficking in marijuana." If
33 the quantity of marijuana involved:
34 (A) Is one (1) pound or more, but less than five (5) pounds, or con-
35 sists of twenty-five (25) marijuana plants or more but fewer than
36 fifty (50) marijuana plants, regardless of the size or weight of
37 the plants, such person shall be sentenced to a mandatory minimum
38 fixed term of imprisonment of one (1) year and fined not less than
39 five thousand dollars ($5,000);
40 (B) Is five (5) pounds or more, but less than twenty-five (25)
41 pounds, or consists of fifty (50) marijuana plants or more but
42 fewer than one hundred (100) marijuana plants, regardless of the
43 size or weight of the plants, such person shall be sentenced to a
44 mandatory minimum fixed term of imprisonment of three (3) years
45 and fined not less than ten thousand dollars ($10,000);
46 (C) Is twenty-five (25) pounds or more, or consists of one hundred
47 (100) marijuana plants or more, regardless of the size or weight
48 of the plants, such person shall be sentenced to a mandatory mini-

38
1 mum fixed term of imprisonment of five (5) years and fined not less
2 than fifteen thousand dollars ($15,000).
3 (D) The maximum number of years of imprisonment for trafficking in
4 marijuana shall be fifteen (15) years, and the maximum fine shall
5 be fifty thousand dollars ($50,000).
6 (E) For the purposes of this section, the weight of the marijuana
7 is its weight when seized or as determined as soon as practica-
8 ble after seizure, unless the provisions of subsection (c) of this
9 section apply.
10 (2) Any person who knowingly manufactures, delivers, or brings into
11 this state, or who is knowingly in actual or constructive possession
12 of, twenty-eight (28) grams or more of cocaine or of any mixture or sub-
13 stance containing a detectable amount of cocaine is guilty of a felony,
14 which felony shall be known as "trafficking in cocaine." If the quantity
15 involved:
16 (A) Is twenty-eight (28) grams or more, but less than two hundred
17 (200) grams, such person shall be sentenced to a mandatory minimum
18 fixed term of imprisonment of three (3) years and fined not less
19 than ten thousand dollars ($10,000);
20 (B) Is two hundred (200) grams or more, but less than four hundred
21 (400) grams, such person shall be sentenced to a mandatory mini-
22 mum fixed term of imprisonment of five (5) years and fined not less
23 than fifteen thousand dollars ($15,000);
24 (C) Is four hundred (400) grams or more, such person shall be sen-
25 tenced to a mandatory minimum fixed term of imprisonment of ten
26 (10) years and fined not less than twenty-five thousand dollars
27 ($25,000).
28 (D) The maximum number of years of imprisonment for trafficking
29 in cocaine shall be life, and the maximum fine shall be one hundred
30 thousand dollars ($100,000).
31 (3) Any person who knowingly manufactures or attempts to manufacture
32 methamphetamine and/or amphetamine is guilty of a felony which shall
33 be known as "trafficking in methamphetamine and/or amphetamine by man-
34 ufacturing." Any person convicted of trafficking in methamphetamine
35 and/or amphetamine by attempted manufacturing shall be sentenced to
36 a mandatory minimum fixed term of imprisonment of two (2) years and
37 not to exceed fifteen (15) years imprisonment and fined not less than
38 ten thousand dollars ($10,000). Any person convicted of traffick-
39 ing in methamphetamine and/or amphetamine by manufacturing shall be
40 sentenced to a mandatory minimum fixed term of imprisonment of five
41 (5) years and not to exceed life imprisonment and fined not less than
42 twenty-five thousand dollars ($25,000). The maximum number of years of
43 imprisonment for trafficking in methamphetamine and/or amphetamine by
44 manufacturing shall be life, and the maximum fine shall be one hundred
45 thousand dollars ($100,000).
46 (4) Any person who knowingly delivers, or brings into this state, or
47 who is knowingly in actual or constructive possession of, twenty-eight
48 (28) grams or more of methamphetamine or amphetamine or of any mixture
49 or substance containing a detectable amount of methamphetamine or am-

39
1 phetamine is guilty of a felony, which felony shall be known as "traf-
2 ficking in methamphetamine or amphetamine." If the quantity involved:
3 (A) Is twenty-eight (28) grams or more, but less than two hundred
4 (200) grams, such person shall be sentenced to a mandatory minimum
5 fixed term of imprisonment of three (3) years and fined not less
6 than ten thousand dollars ($10,000);
7 (B) Is two hundred (200) grams or more, but less than four hundred
8 (400) grams, such person shall be sentenced to a mandatory mini-
9 mum fixed term of imprisonment of five (5) years and fined not less
10 than fifteen thousand dollars ($15,000);
11 (C) Is four hundred (400) grams or more, such person shall be sen-
12 tenced to a mandatory minimum fixed term of imprisonment of ten
13 (10) years and fined not less than twenty-five thousand dollars
14 ($25,000).
15 (D) The maximum number of years of imprisonment for trafficking in
16 methamphetamine or amphetamine shall be life, and the maximum fine
17 shall be one hundred thousand dollars ($100,000).
18 (5) Any person who knowingly manufactures, delivers, brings into
19 this state, or who is knowingly in actual or constructive possession
20 of the below-specified quantities of any of the following immediate
21 precursors to methamphetamine or amphetamine (namely ephedrine, methy-
22 lamine, methyl formamide, phenylacetic acid, phenylacetone, or pseu-
23 doephedrine) as defined in section 37-2707(g)(1), Idaho Code, or any
24 compound, mixture or preparation which contains a detectable quantity
25 of these substances, is guilty of a felony which shall be known as "traf-
26 ficking in immediate precursors of methamphetamine or amphetamine." If
27 the quantity:
28 (A) Of ephedrine is five hundred (500) grams or more;
29 (B) Of methylamine is one-half (1/2) pint or more;
30 (C) Of methyl formamide is one-quarter (1/4) pint or more;
31 (D) Of phenylacetic acid is five hundred (500) grams or more;
32 (E) Of phenylacetone is four hundred (400) grams or more;
33 (F) Of pseudoephedrine is five hundred (500) grams or more;
34 such person shall be sentenced to a mandatory minimum fixed term of
35 imprisonment of ten (10) years and fined not less than twenty-five thou-
36 sand dollars ($25,000). The maximum number of years of imprisonment
37 for trafficking in immediate precursors of methamphetamine or am-
38 phetamine in the quantities specified in paragraphs (A) through (F) of
39 this subsection (5) shall be life, and the maximum fine shall be one hun-
40 dred thousand dollars ($100,000). If the quantity of pseudoephedrine
41 is twenty-five (25) grams or more, but less than five hundred (500)
42 grams, such person shall be sentenced to a term of imprisonment of up
43 to ten (10) years and fined not more than twenty-five thousand dollars
44 ($25,000).
45 (6) Any person who knowingly manufactures, delivers or brings into this
46 state, or who is knowingly in actual or constructive possession of, two
47 (2) grams or more of heroin or any salt, isomer, or salt of an isomer
48 thereof, or two (2) grams or more of any mixture or substance containing
49 a detectable amount of any such substance is guilty of a felony, which

40
1 felony shall be known as "trafficking in heroin." If the quantity in-
2 volved:
3 (A) Is two (2) grams or more, but less than seven (7) grams, such
4 person shall be sentenced to a mandatory minimum fixed term of im-
5 prisonment of three (3) years and fined not less than ten thousand
6 dollars ($10,000);
7 (B) Is seven (7) grams or more, but less than twenty-eight (28)
8 grams, such person shall be sentenced to a mandatory minimum fixed
9 term of imprisonment of ten (10) years and fined not less than fif-
10 teen thousand dollars ($15,000);
11 (C) Is twenty-eight (28) grams or more, such person shall be sen-
12 tenced to a mandatory minimum fixed term of imprisonment of fif-
13 teen (15) years and fined not less than twenty-five thousand dol-
14 lars ($25,000).
15 (D) The maximum number of years of imprisonment for trafficking
16 in heroin shall be life, and the maximum fine shall be one hundred
17 thousand dollars ($100,000).
18 (7) A second conviction for any trafficking offense as defined in sub-
19 section (a) of this section shall result in a mandatory minimum fixed
20 term that is twice that otherwise required under this section.
21 (8) Notwithstanding any other provision of law, with respect to any
22 person who is found to have violated the provisions of this section, ad-
23 judication of guilt or the imposition or execution of sentence shall not
24 be suspended, deferred, or withheld, nor shall such person be eligible
25 for parole prior to serving the mandatory minimum fixed term of impris-
26 onment prescribed in this section. Further, the court shall not retain
27 jurisdiction.
28 (b) Any person who agrees, conspires, combines or confederates with an-
29 other person or solicits another person to commit any act prohibited in sub-
30 section (a) of this section is guilty of a felony and is punishable as if he
31 had actually committed such prohibited act.
32 (c) For the purposes of subsections (a) and (b) of this section the
33 weight of the controlled substance as represented by the person selling or
34 delivering it is determinative if the weight as represented is greater than
35 the actual weight of the controlled substance.
36 SECTION 6. That Section 25-2703, Idaho Code, be, and the same is hereby
37 amended to read as follows:
38 25-2703. DEFINITIONS. When used in this chapter:
39 (1) The term "animal remedy" means any drug, combination of drugs,
40 pharmaceutical, proprietary medicine, veterinary biologics, or combination
41 of drugs and other ingredients, other than for food or cosmetic purposes,
42 which is prepared or compounded for any animal use except man, or materials
43 other than food intended to affect the structure or any function of the body
44 of animals other than man. This term does not include medicated feeds.
45 (2) The term "brand name" means any word, name, symbol or device, or
46 any combination thereof, identifying the commercial feed of a distributor or
47 registrant and distinguishing it from that of others.

41
1 (3) The term "commercial feed" means all materials or combination of
2 materials that are distributed or intended for distribution for use as feed,
3 or for mixing in feed, for poultry and animals other than man, except:
4 (a) Unmixed whole seeds and physically altered entire unmixed seeds,
5 when such whole or physically altered seeds are not chemically changed
6 or are not adulterated within the meaning of section 25-2707, Idaho
7 Code, or misbranded within the meaning of section 25-2708, Idaho Code.
8 (b) Seeds mixed and planted as such mixture, grown and harvested as one
9 (1) crop, and processed as one (1) mixture when not adulterated within
10 the meaning of section 25-2707, Idaho Code, or misbranded within the
11 meaning of section 25-2708, Idaho Code.
12 (c) All hay, except commercially dehydrated legumes and grasses and
13 when not adulterated within the meaning of section 25-2707, Idaho Code,
14 or misbranded within the meaning of section 25-2708, Idaho Code.
15 (d) Whole or ground straw, stover, silage, cobs, husks, hulls, wet or
16 pressed beet pulp, pea screenings and beet discard molasses when not
17 mixed with other materials and when not adulterated within the meaning
18 of section 25-2707, Idaho Code, or misbranded within the meaning of sec-
19 tion 25-2708, Idaho Code.
20 (e) Live, whole or unprocessed animals when not adulterated within the
21 meaning of section 25-2707, Idaho Code, or misbranded within the mean-
22 ing of section 25-2708, Idaho Code.
23 (f) Animal remedies when not adulterated within the meaning of sec-
24 tion 25-2707, Idaho Code, or misbranded within the meaning of section
25 25-2708, Idaho Code. Animal remedies for pets, specialty pets, and
26 equines that include ingredients from industrial hemp as defined in
27 section 22-1703, Idaho Code, and as described under the definition
28 of " from tetrahydrocannabinols or synthetic equivalents" in section
29 37-2705(d) pursuant to section 37-2707(i), Idaho Code, are not consid-
30 ered adulterated.
31 (g) Individual mineral substances when not mixed with another material
32 and when not adulterated within the meaning of section 25-2707, Idaho
33 Code, or misbranded within the meaning of section 25-2708, Idaho Code.
34 (h) Certain processing byproducts or production waste, identified by
35 the director in rule, without further processing, received by the end
36 user directly from the food processor when not adulterated within the
37 meaning of section 25-2707, Idaho Code, or misbranded within the mean-
38 ing of section 25-2708, Idaho Code.
39 The director, by rule, may exempt from this definition, or from specific
40 provisions of this chapter, commodities and individual chemical compounds
41 or substances when such commodities, compounds or substances are not in-
42 termixed with other materials and are not adulterated according to the
43 provisions of section 25-2707, Idaho Code, or misbranded within the meaning
44 of section 25-2708, Idaho Code.
45 (4) The term "contract feeder" means a person who as an independent con-
46 tractor feeds commercial feed to animals pursuant to a contract whereby such
47 commercial feed is supplied, furnished, or otherwise provided to such person
48 and whereby such person's remuneration is determined, all or in part, by feed
49 consumption, mortality, profits, or amount or quality of product.

42
1 (5) The term "customer-formula feed" means commercial feed that con-
2 sists of a mixture of commercial feeds and/or feed ingredients, each batch
3 of which is manufactured according to the specific instructions of the fi-
4 nal purchaser, end user or consumer. Customer-formula feed does not include
5 commercial feeds that are used as ingredients in other commercial feed or are
6 offered for retail or further distribution.
7 (6) The term "department" means the Idaho department of agriculture.
8 (7) The term "director" means the director of the Idaho department of
9 agriculture or the director's authorized agent.
10 (8) The term "distribute" means to offer for sale, sell, exchange or
11 barter commercial feeds in or into this state or to supply, furnish, or oth-
12 erwise provide commercial feed to a contract feeder.
13 (9) The term "distributor" means any person who distributes.
14 (10) The term "drug" means any article intended for use in the diagno-
15 sis, cure, mitigation, treatment, or prevention of disease in animals other
16 than man and articles other than feed intended to affect the structure or any
17 function of the animal body.
18 (11) The term "feed ingredient" means each of the constituent materials
19 making up a commercial feed.
20 (12) The term "label" means a display of written, printed, or graphic
21 matter upon or affixed to the container in which a commercial feed is dis-
22 tributed or on the invoice or delivery slip with which a commercial feed is
23 distributed.
24 (13) The term "labeling" means all labels and other written, printed, or
25 graphic matter upon a commercial feed or any of its containers or wrapper or
26 accompanying such commercial feed. This includes statements and promotion
27 on company websites or other internet-based customer interfaces.
28 (14) The term "manufacture" means to grind, mix or blend, or further
29 process a commercial feed for distribution.
30 (15) The term "medicated feed" means any feed that contains drug ingre-
31 dients intended or presented for the cure, mitigation, treatment, or preven-
32 tion of disease in animals other than man or that contains drug ingredients
33 intended to affect the structure or any function of the body of animals other
34 than man.
35 (16) The term "mineral" means a naturally occurring, homogeneous inor-
36 ganic solid substance, essential to the nutrition of animals, having a def-
37 inite chemical composition and characteristic crystalline structure, color
38 and hardness.
39 (17) The term "mineral feed" means a commercial feed intended to supply
40 primarily mineral elements or inorganic nutrients.
41 (18) The term "official sample" means a sample of commercial feed taken
42 by the director or an authorized agent in accordance with the provisions of
43 section 25-2709, Idaho Code.
44 (19) The term "percent" or "percentage" means percentage by weight.
45 (20) The term "person" includes an individual, partnership, corpora-
46 tion, firm, association and agent.
47 (21) The term "pet" means any domesticated animal normally maintained
48 in or near the household(s) of the owner(s) thereof.
49 (22) The term "pet food" means any commercial feed prepared and dis-
50 tributed for consumption by dogs and cats.

43
1 (23) The term "pharmaceutical" means any product prescribed for the
2 treatment or prevention of disease for veterinary purposes, including
3 vaccines, synthetic and natural hormones, anesthetics, stimulants or de-
4 pressants.
5 (24) The term "product name" means the name of the commercial feed that
6 identifies it as to kind, class or specific use.
7 (25) The term "purchase" includes taking by sale, discount, negotia-
8 tion, mortgage, pledge, lien, issue or reissue, gift or any other voluntary
9 transaction creating an interest in property.
10 (26) The term "purchaser" means a person who takes by purchase.
11 (27) The term "registrant" means that person, manufacturer, guarantor,
12 or distributor who registers a product or products according to the provi-
13 sions of section 25-2704, Idaho Code.
14 (28) The term "sell" or "sale" includes exchange.
15 (29) The term "specialty pet" means any domesticated animal pet nor-
16 mally maintained in a cage or tank, such as but not limited to gerbils,
17 hamsters, canaries, psittacine birds, mynahs, finches, tropical fish, gold-
18 fish, snakes and turtles.
19 (30) The term "specialty pet food" means any commercial feed prepared
20 and distributed for consumption by specialty pets.
21 (31) The term "ton" means a net weight of two thousand (2,000) pounds av-
22 oirdupois.
23 (32) The term "veterinary biologics" means any biologic product used
24 for veterinary purposes, including but not limited to antibiotics, antipar-
25 asiticides, growth promotants and bioculture products.
26 (33) Words importing the singular number may extend and be applied to
27 several persons or things and words importing the plural may include the sin-
28 gular.
29 SECTION 7. An emergency existing therefor, which emergency is hereby
30 declared to exist, this act shall be in full force and effect on and after its
31 passage and approval.

[DELETED: EOFTESEOFIhLeFtRrSn-2NTEHEOFREBLN.4YRNADRNAGTOTESTKRMLCSA;AGTE3OC,BYTEANOFANWCR9,TE3,IOCOPEASTTEADLEI,TOPEFRSYC,TODET,TOAETEUEOFCSASPSADRDASURCNCOPEFRANECVNSMADP,THPSRGQGC,TOESRGPRR,T,ADTTR,TOEHPSRGLNLYADTESDOFC,TOPEFRAQDPTEEFDADREN,TOEHPGN,TOCYTTISADOSATRDTOCRC,CSP,ORMLC,TOEHPSRGTEUEOFHPE,ADCNORP,TOEHPGMLCSPTC,TOEHPSRGMLCSCRC,TOPEFRACYADBDCKOFADDC,TOESRGMLCSCDRSADAREP,TOEHPSRGALTORSLCSC,TOPEFRTEINADTNOFC,CSP,ADMLCSD,TEFRCLE,TOPEFRAR,TOPRRGAYADFRCNT,TOPELLI,TOPETTCNASAENTP,TOPEFRP,TOPEP,TOPEPDTOPES;AGSN3,IOC,TEPSFMSEIINTEUMCDS;AGSN3,IOC,TOREPSRGSEIIINTEUMCDSSA;AN3,IOC,TOPEESADAGSN3,IOC,TOPEANE;AGSN2,IOC,TOPEACTCERDDGANEeItEdbyteLeofteSeofIN1.TtTe3,IoC,b,adteseishyayteantoofaNWC,tobeknadddasCr9,Te3,IoC,adtordasfR9TKRMLCSA]
[DELETED: .STTE--LEIT--SYC.()Tscrslbeknadmybecdaste"rMlCsA)Inegtsc,itisteitofteletetep,t,adueofcsadc,wntelspdbytsc,frtepeogmlcsttaetoIopssmsshhc.Psweasaepdbyancewhtepsoftscrwln,frshaehdtovetepsofcr2,te3,IoC,oyorpnofsel,llo,oraerytotepsoftsc)Tepsoftscrsdbecdinteltmtwhteitpdintss.D.Frtepsoftsc,usctoer)""msapccyorptudtocnnomnasedeofcsoracsptinabrp)"rp"msap,p,orflpewhmebsehcgnometnasedeofcsorsp)""mstebdofpyortednofodpllsagonbfoftebdofp)""or""msangcdfncsadh)""msmaasddinsn3,I)"sp"msaptddf,ormeb,pgcspsorpsofteptt)Isidfrhnu;a)Cscsort)"yl"msapcorpes,ac,cl,apcp,orapcp)""mstesedtofhhadw)"dc"msanilw)Isddbyaptwhamlcsptcdaepsc;a)Rswhtedtpttosn3,I)"gp"msq,r,adfyofanfrardttofcsinamldmoracsptinamldef)"cvns"mstesmedbn3,IoC)"dmlcsp"or"lcsp"msanilldurcr1,te5,IoCoisedbyamlcsp]
[DELETED: )"dmlhht"msanillrte5,IoC,wopsmlhhsswnteofteisl)""hstesemgaspdinsn3oC)"lc"mscsinamldefmorsptinamldef)"lcsc"msamlcsptcdorlcscrc)"lcsc"mstehrofamsc)"lcscrc"msanolcdt)Tedtistoanilwmamlcsptcrdsasaddc;a)Iscdtoteecvns)"lcsd"msadeudtog,i,otcsinamldefmoracsptinamldefmoradeudsyfrtemlvnofr,udcsf)"lcsptc"msanolcdt)Tedtistoanilwhaqgc)Iscdtoteecvns)"lcst"mscsinamld,acsptinamldef,oramlc)"ldef"mscsoracsptifmsefrmlttasddinps(,(d()oftss.Tete()secsofmefmmybepdadodbycyorbyacno.Alfsmtbepdinseormedefhscadctcdctaspdintss)"dpdfmofmlc"m)Acdolnttoedoehd()msprc)Aldsnnttoedoehd()msprc)Atlpnnttoedoehd()msprc;o)Aslpnnttoedoehd()msprc)"dpdfmofmlc"m)At,uptotn()tsprp)Ac,uptotn()csprp)Agsc,gsrrc,oeinaceorrrcds,uptotn()p)B,r,orwxnttoedoehd()glwtprpeorc;o]
[DELETED: )Atlpnnttoedoehd()msprc)"dmlcsf"isagltmttmetdptofafecsp.Itmtbepdinabrpkorttpeorc.Ehilbrorttpeorcrm)Cnascadctwtttdsntee()gmprehilbrpkadfe()grcepeordsntedto()gsprttpeorcradttvsbynometntt()fmtesdw;a)Beldwhabettpsincdtoaniyclsmadteilbtadwtorttpsorctadw)Amldefmmtbemding,m,o)"ldef"isapnofudcrt)Temlcscrhsryrdfmtrpkfru;a)Dsntedteqyddintss)"ldef"dsnti)Ayudcsfroeoftebrotpeorc,etasoepntss;o)Apsofvgcdcsolvaaceororsrptordebypgtecdcsolceororsrptordnaveorvgd)""m)Ani,af,ap,ana,af,,aldlyc,orac;o)Anatoraneeofani,af,apna,af,at,aldlyc,orac)""hstesemgaspdins,IoC)"dpteef"mstefdedin3,IoC)"gc"msacnddins,IoC)""or""msaseddfsadcdinaptoftegsC,aswlasssoftesscdintecsp,orintsesofC,s.arscs,d,adtriswhsrclseasddin3,IoC]
[DELETED: .A.Ngaypnoflwtot,tep,t,adueofcsadc,aswlasasrdtotep,tdueofcsadcsp,aeadaspdintrfrtepsidintsc.ECVNSM--P.()Teblehanecvnsmttcswhtsoftss.Anegsmmybeudoradtywhtepsoftss.Tebdm,asn)Cewhtednofpgtodpasnfratyprtodpadmnteens;a)Statyprwomsterscntesnidurph()oftss)Tebdmteet,onorbeJy1,2,teecvns)Asanilorapragonteiftoayframlcsptc)Asaniltoaytorwamlcspdinaewhsn3,IoC)Asaprtoasteecvnsnaewhbdr)Psast)Tebdtoteetnytocyottebsadrsurtsc)Tedttoteetnytocyottedsfsadrsurtsc;a)Lgbsfrpsaspdinb)Psastoseorlllwe;a)Csardehteapnastedettistepnwoastedeadteilwstepna)Tebdmyredddatttesmcrtepeo)Cgmlr;a)Pgtertrdbysn3,IoC)Tebdslper,sttoleaoe)Telsonastotedainteecvnsmasddintss;a)Ssadpstoeeaeinofalrginorrginaspntss)Aypnwokyadiyrsayininteecvnsminvnoftssnisgyofam)Aypnworyorwhgsnersaninteecvnsminvnoft]
[DELETED: nisgyofani.Tebdslehshinpsinr,sttolea)Aypnwoosorastooninfeecvnsmbymnorfdiyofam)Aypnwoosorastooninfmtcvnsmfrapeortnapetrasisgyofam)Etaspdinph()oftss,apyntkyadiyu,r,p,oroeaetoayorpninodfmteecvnsmfraypeortnapesdintss)Ehsevnoftssni)Am;a)Sttoaclpynttoedfetdds()Tebdsldeaclvnoftssniewhcr5,te6,IoC)Clpsadurtssnslbedoteqdpteefdedbys,IoC)Tssndsntptapnwoosimteecvnsmursn(,(r()oftssnf)Igteinintepsmlctoefrasbyapnadtorwtemlcrf)Pgteintoapninaewhtsoftehhiepyadayatof1;o)Dgorsgttinonteptwep.QGC.()Bydgaprcnursn()oftssnfrwhteueofmstottssisd,teledsntcyset)Ctsceecyssteeyofamlcsttfrtec;o)Amlcsttwlt,c,orpyaec)Frtepsoftsc,ehoftefgcnbecdaqgcniftecnisa)Adiedyse()orhniyvs()Asd)Acllss()A)C]
[DELETED: )C)Ccp)Csdeoruec)Eyordgs)Messordgmes)Nattisntsyretotlt,etfrnardt)P)Cdclvgs;o)Cdhss)Pcssdr()ttisbgtdadbyaldmlhhttadt)HsbnddbyahhceprormlhredorcdbyteUdSsdtosa;o)Hsbnddorcdbyaprwoi.Aldbeorbdp.Aldptwhadld.Aldclslwrwhad;o.Aldadperdnewoidtopewntepcmlhgs)Atliswetepscnisntedtewhorwtormlt)Acnrginteilrghec)Arecnordet)Asfrtntohdtd()isinteUdS,asddinsn56oftef,d,adcca;a)Isntaymddettasu.Clmsortnosoro.Pli;o)Ardgmlcnasddbyap.PRRN--TG--TTR.()Aprmyntrdamlcststebdrsteprinaewhtss)Tebds,wnfn()dsartedyonwebdrsacdanfmap,rrtriftep)Pstotebdtepsneada)Pstotebdartdgtepscnoftetgrsddinsn()oft;a)Pstotebdeetttep)Hsteaytoweap]
[DELETED: )Isldtopeacds;a)Hstea,inaewhteissfp,topeaseIIcds)Asacnpttor,aprmtcetgasddbytebdincnwhoraelgb,whtgmtc)Tepsoftsc)Glinatmlcsurflads)Teltscrhonteedsmalc,igrsadb)Rsfrmlcsasitrstotecgceofaptinpnm,rkm,pla,orpec)Btpsfrrgtefmaddeofmspsbdonteqgcnugamlcsr;a)Orinasddbyteb,incnwelgb)Aprmyrdmlcstoanilurtscrinteceofaptrpoyarteprhscdadddintepsmdathatoftepscnadmlhdonteaesdofcefrtepsc)Etaspdinph()oftss,aprmyntaettteprrsmst)Frpsofph()oftss,tecftefgthawedsntcea)Aqgcnttteprt)Ascsyrgmlcsu;o)Inataptorseodbytep)Apsrnurtssnest)ysartedyonwhtebdister)Tebdslrwapsrniftep)Asfrr)Iseefrarnurtss,igmganudleasddinsn()oftss)Cstotebdinacdrlatteinrdinsn()oftssnieorustei;a)Ssartdgtecnofaytgflasmyberdbyteb)Tebdmyreternofaprwofstncewhtersoftss)Aprmyntreaycnorbtfrtsmlcsttrnf]
[DELETED: )Amlcspyorano,ano,ad,dm,ane,oranatofamlcsp)Arp.LSONLY--SDOFC.()Aprddinsn()oftssnisntsttotefgsyfrvgafllworrnttwdotr,p,ordgmlc,amlcsp,oracddgttteUdSsfddganhsnta)Clorcll;o)Lessurte5,IoC)Telsoflyddinsn()oftnayt)Aprworsamlcstttoap;o)Aldmlcsptormlcspynewod,inamlcsp,thcsinamldefmoracsptinldefmtoamlcscrinahtsc)Ngintssnorcrrsorinaywynstyofanilddinsn()oftssntouereadoyceintettofaptwomyheaqgcna)Frwmaprhsrdormtcrrgamlcst;o)Whwmaldmlcsptormspynehsidintedgordgosoracsp.QDPTEEFD--REN.(eishyedintesetyteqdpteef)Msintefdedbytssnslcto)Msddintefdurtsc)Astelemstotef)Clpsadpttosn3,IoC)Teitddinsn()oftss)Itedoniemsintefdslbeddint)Tebdmyuemsintefdoytofdtebsrsurtsc.Tebdslretedmtefdfrtedsaeesurtsc)Fsadbytscrslbestinasnnt,tocresrdtoinadetosc]
[DELETED: .NNFRMLCEORGTE.()Frpsofmlc,iganont,su,inaewhtsc,ofcsinamefmoracsptinamldef)Iscdteetofteadueofayormnudattednofap;a)Dsntceteueofanitseoroyanilfmndmlc)Ngayorpnoflwadetaspdinph()oftss,teseoraypnmtttanesueofmlcsinaewhtscrintesewyteseorplsntseeueofosado)Ph()oftssndsntayweadjeflfgfrteesp.NOIER.Ngintscrrni,atya,oranertopyfrorrepeofc,acsp,oramlcsd.NOETONUEOFHPET--CL--A.()Ngintscrpsani)Fmp,s,p,a,orughtttisllurfll;o)Fmp,s,p,a,oruglptttisadbyteUdSsfdadd)Ngintscrrsoroeastep,d,ordgofaptttteUdSdaddganhsa.MLCSPTCD--FS--S.()EeJy1,2,tedtslieamlcspdoracrcdtoanilddinsn()oftnwnfn()dsartedyonwhanilwsteeycaintssnorsn3,I,ssacdaninaewhtssnon3,IoC)Aniliseeframlcsptcdi)Teilisatltte()ysofa)TeilisanIor)Teisprrsttwhmsinaewhsn()oftss)Teilssanatsgttteidteinddinsn()oftss)Teilpstotedtafeinanatstbyt]
[DELETED: )Anilwoiseeframlcscdposn()oftssnorteispragoeisbfslstananframlcdtoted)Thanecancdtoteecvns;a)Whini)Teasn,g,a,ada;a)TenrofteasfmofinttivdUdSsf-orsdpoi,igadsl,aUdSsp,dSsptc,oraUdSsmyinc)Tordamlcstttoaptortorw,aprm)Bergcsinamldefmorsptinamldef)Vytepsvdfmofindnsn()oftss)Rwayrdrdtotepti.Teecvns;a.Ordsrgorcdssorclvswecdssaei;a)Crterninltoftepsqgcnadhyofmlcsadceu;a)Seintepsrntttep)Ssfmaqgc,igteteogc)Mybtfmttwhcsoracsptinascmldef.Teprmetemldefmteptisadtousmystoe(,to(,oralte()csofmlc,wha.Ldpdfmofmlc.Sdpdfmofmlc;a.Udmlcsf)Amlcscdtttedtisurtssnisvdfrtelro)Anatoftettteprd;o)Te()m)Amlcsptcdisrei,atteteo,tecrmstersofsn()oss)Acrddinph()oftssnmyrwamlcsptcdagtoapseyted)Acrursn()oftssnworsamlcsptcdmtpytotedtarlfei]
[DELETED: natstbyted,whmyntedtectoftylraebnofrlincntotlanp)Acrurtssnmtcytecdmlcscdwhtepsnewnegisadbytsc)Acrurtssnmypsortnaewhtscradternuec,csinamldef,acspnamldef,oramlcsd)Toasteqgcnugtemsttr,amlcsprmyuecsinamldef,amsptinamldef,oramlc)IfaldmlcspyisntogwnteonadarJy1,2,orisogintesebtnnoehd()msofacspla,rurtssnisntsttopnfrtepnofuptoasy()dysyofmlc,i)Nometnfrtd()msofT,wybeinsdpdfmofmlc,ldpdfmofmlc,oracnofb.TCrointemlcsslbeddbertp.Teptmtdyalltyssteatoftladcntescmlcsf)Nometnsy()gsofudmlcrcgtopt()orlsT)Ifatyi,h,orcrptwhteanoftep,uptotytd(sofTCinpdmlcsweehilsgoftepdmlcscsnomnoehd()msofT;o)Madgp)Ted,incnwhteb,slehb,sttolea,apstopeinrgtefgtoanilrgamlcsc)Rsadwhmlcst)Teftttacslgasaqgcndtstttmlcsttisaneetrcefrttc;a)Orrtwsadsyi)Tedtmyehpsbyretoittnadiepsoftss)Apnmysttotedtarttoctlrhsyugmlcscrdatttcvnsmc]
[DELETED: )Ted,incnwhteb,wlrwtddinph()oftssntodrtemlrhsyisv)Iftedtadtebdmeadnurph()oftssntttemlrhsyisvedtslnyehrtcragfrtscttopeintes)Tedtmyr,frtepsofasyddiss,inatacrurtssnwstopeurph()oftss)Ted,incnwhteb,myehssframlrhssvybyr,sttolea.MLCSCRCD--RN--R-R.()Acrddinsn3,IoCydeuptoto()istoseasaddcrtecrifaprdst,detopldyorueh,tecrnsaetoontemlcsttttteprr)Anilwotedtrsasaddcrurtss)Mycyavdmlcscrc)Inaewhtsc,myp,t,oraeptinteueofcsinamldef,actinamldef,oramlcsdeonbfoftedgmlcsc)Myntceafetoaniltoatasteisddcrorfrasettteddcrpsinrntotereasaddc)Myatrtfmtedgmlcrfrdtcsteddcrisfragwhtedgcsmlueofc;a)IsntsttopnfrtepnofteffaldmlcspyisntogwnteonadarJy1,2,orisogintesebtnnoehd()msofacspla)Nometnfrtd()msofT,wybeinsdpdfmofmlc,ldpdfmofmlc,oracnofb.TCrointemlcsslbeddbertp.Teptmtdyalltyssteatoftladcntescmlcsf)Nometnsy()gsofudmlcrcgtopt()orlsT)Ifatyi,h,orcrptwhteanoftep,uptotytd(sofTCinpdmlcsweehi]
[DELETED: lsgoftepdmlcscsnomnoehd()msofT;o)Madgp)Tedts)Wnfn()dsartedyonwhanisacdanincewhtsseamlcscrcdtoteatiftea.Isddasacrursn()oft.Iseeframlcscrcdun()oftss;a.Cswhtss;a)NyteIosepeofehiltttedtrsasaddc)Tedtmteettamlcscrcsteinddinsn()oftss)Aniliseeframlcscrcdiei)Isatltte()ysofa)IsanIor)Pstotedtafeinanatstbyted,pectofteclhyadbdckddinsn3,IoC)Ssanatsgttteatrdteinddinsn3,IoC;a)Hsntbncdofamrorfydgdettisafyurerseorfll,u)Teilcsayidseto()ormsbetedyonwhteilsstea;o)Teoewsfrctttisadurt)Aneeatframlcscrcds)Stananframlcscrcdtottthanecancdtoteecvns;a)Sttefgininsha)Teasn,g,a,ada;a)Ten,g,a,adasoftecrddinsn3,IoC,woddtea)Etasoepdbytsc,amlcrcdtttedtisurtssnisvdfrtro)Anatoftetttecrddinsn3oC,woddtecrd;o)Teatoftergbetecdoftecrddinsn3,IoC,e]
[DELETED: )Ifaddcrmstersofs)oftss,teddcsmlcscrcdrsayattetetecrddin3,IoC,woddtec)Rstecsc;a)Rstecsd,inaewhph()oftss)Tedtslpeamdintecdrlpoawacrddinsn3,IoC,wohdacrt)Sytttecrrstecsd)Reacsd;o)Deanwc)Tedtmyreamlcscrcdiftdc)Vstepsoftsc;o)Hsbncdurseorfllwfrctttitadbytscradtti)Af;o)Arteeedeoftsc,amrfgd.DDCR--CLHYADB.Ehatframlcscrcdslsttolhyadbdckasddbyted.Ttwlasanatafeinanatstbytedrteclhyadbdc.MLCSCD--PTADDDCS--REP)Amlcscrwopscsinamldefmoracsptinamldefmtecrpdurtsc)Mtcytecsmlcscdwneginasadbytsc)Mtc,whtecsinamldefmosptinamldef,allttistttecsorcsptwssdfmallcsp;a)Myp.Nometnfrtd()msofThmybeinsdpdfmofmlcdpdfmofmlc,oracnofb.TeCCrointemlclbeddbytertp.Teptmtdyallttcyssteatoladclintescmlcsf]
[DELETED: .Nometnsy()gsofudmsfrcgtopt()orl;o.Ifatyi,h,orcrptwhtnoftep,uptotyt)msofTCinpdmlceehilsgoftepdmscsnometnoehd()mfT)Amlcscrwopscsinamefmoracsptinamldefminvnoftssnisgyofaninadsttoaffoehdds()Amlcscrwopsmetnteadinph()oftssnbtnometeteatadinph()oftsssgyofamradsttoafeofoetdd)Anilwoisgyofavnpttoph(r()oftssnisntgyofavnofcr2,te3,IoC,frtectugtepyddirp)Amlcscrwopsmetntettadinph()oftssnissoanaepypdbycr2,te3,IoC)Amlcsptcrmyntctulcsfrinpcorinvwoftep)Ifamlcscrcgtecscscsinamldefmoracsptinldefmincewhtepsofsn()ossnoramlcsdettcswhtecrcsp)Teisarepntttecrpst,csp,ormlcsdel;a)Teisnopec,bdsyontecspnoftecsinmldef,csptildef,ormlcsd,tobetttriseginila)Ifapeorssanilwopscsimldef,acsptinamldeframlcsdeadteilrstoteprttteilhsavdmlcscdbttldsnthetemlcscdinteinatteteoftespbytepeo,tnteprmtattoasteecvnsmtewrteilhsavdmlcsc)Iftepeorisaetovyttteildnph()oftssnisavdmlcsc,tntepeo]
[DELETED: )Myntatorteteiliocyfrternttteilisinpnofcsinldef,acsptinamld,oramlcsd;a)Myntsetec,csp,ormsd)Iftepeorisuetovyttteilddinph()oftssnisavdmlc,tntepeormyrrteilfrpnorieacnttwdbeaeurtecsfranilwodsnthdavdmlc.Tepeormyaoseayc,csprmlcsd.H,teilmyntbetoc,adayclctorcnmtbednpnofpfttteilhsavdmscdtotepgaywhjnorttorc)Amlcsptcrmteettmsissdinshawyttitisietomsoftsh,etframroftehdwoi)Amlcscrc;a)Agtemlcsptcrwhaeofmlc.LTORSNMLCSC.()Ifamscdisltors,temlcscrmtreltorsncdtoted)Unrgtertddinsn()oftss,tedtsldetemlcscdasltoninteecvns)Amlcspyatmyceamlcdttisddasltorsninaewhsn(ftssnifanilpstecdattemlc)Tortanwmlcsc,temlcscrddinsn()oftssnm)Ceafmasddbyted;a)Pyafeinanatstbyted.C,CSP,ORMLCSDEINADT.()Tebdslehr,solea,frteinofc,csp,admlcsdsiotss,adaypnagtoadincewhshrsslbecdtobgincewhtsc)Tebdslehr,sttoleartetnofc,csp,admlcsadtss,adaypnagagtoadincewhshrsslbecdtobeagincewht]
[DELETED: )Tebdmyehbyr,sttoleasfrtgcsinanudfmoramldef,acsptinamldef,oramsdetoeetttec,csp,ormsderssefrhncnoru)Ifapnisortsc,csp,olcsdsinamrttdsntcywhtepftss,tntepsoftscrslnta,ahpnslbesttotepsofcr2,te3,I.ET--C.()Etaspdintsc,itisulframlcscrtosloroetoarmlcscrcsinamld,acsptinamldef,amlcsd,oraycsrerginorfmamlcsd)Etaspdinph()oftss,amlcscrwovstepsofsn(ftssni)Gyofam;a)Sttoafeofoetdds()Anilisntgyurph()oftssfteilisaddcradgsteptddinsn()oftssntotemlcscrwoddteilasaddc)Anilwoisgyofavnddinp)oftssnisntgyofavnofcr2,t,IoC,frtectugtev)Itisulframlcscrtosloroegetoanlcscrcsinamld,acsptinamldef,amlcsd,oraycsrerginorfmamlcsdmlcscrwovstepsoftsssstt)Ayaepyurcr2,te3,IoC;a)Unc,ptrnoftemlc.Ehmlcscdidmtieawgvntecdttptrnoftecdmyrtfmavnoftss.R.()ByJy31ofehy,tebdadtedtslrttoteseadheofrshhaecso)Tenrofasadrlasfdfrmlcsc)Tenrofqgpsadddc)Teneoftedgmlcsofteq)Teaeadcyofreofc)Tenrofmlcscsr]
[DELETED: )Tenrofpspgrsfrqgp)Tenrofleasadrlleasr)Tenroflstebdhsidinehc)Tenroflstebdhsr;a)Teesidadrsgdfmtemsp)Tebdadtedtmyntiepyinintertddintss.RG--T.()Tebdadtedtadtoper,sttolea,asnytoittepsoftsc)Tebds,incnwhteIosepearrta,dpadortgontepsosc,igtgfrlwetp.IS--ASNTPD--P.(gaypnoflwtotec,apnagueanofadincewhtepsoftscsntsttopnurselworlloefrayadadctc)Tepsoftscrslntbecdtoptnt)O,n,orbeinalplclofayv,rdt,syhye,orvlwrteieofc;o)Uecsinaypcaaussypdbdr)Apnwocsanatddinsn()oftssnissttoshpsasaepdbyl.P.()Apeormyntedayseolr,igtepeost,t)Etanatorseofcsorctayinontesebsofaytttepeorbsteavnoffllwiftepeorhsrntettteayisincewhtsc)Eealwttrsanisrttoa,orpsafmbdsyonteispnorufmlcsinaewhtsc;o)Peayinorllstrdtoanayddinph()oftssntoayfllwetayorpge)Aseayorplsnmyntteaeatapnfrpgaplsetoamlcyontesebsttteseisavnoffll]
[DELETED: .P.()Apnslntbesttoa,orpyinaymrorddayrtorpgwtlnaclpyordyanby,o,orpllgbdorb,fratadbytsc)Nol,sld,pccrs,seinofhre,orcyceodpttocr2,te3,IoC,m)Retoe,retolet,oroepeaprayatadbytsc,usfgtodosowdvefllworrnorcealsofamyorldbturfllworr;o)Bepdorddaybturselworlloefre,lgt,oregamlcsc)Anermyn)Deatapninh,t,oraytrcnofe,oroepeap,frayadbytsc,uscewhtsphwyteerfmamyorldbrfllworr;o)Bepdorddaybturselworlloefregamlcsc)Apnoeedtocyo,orvnorpgtew,amrmyntbeddcyorvnorpesyfrctadurtsc,nrmyteb)Afgorpnofaesyfrctadusc;o)Afgorpnofntorcdetsrctadurtsc)Apnwousmlcsasadbytsclbeadaltesersurselwadlloeaepnwdbeadiftepnwesypdaplmnasitpst)Ayinwhapse)Dgtgbyapse;o)Dgtgrdbyaysel,llo,s,orseorllgto)Ngtepsofsn()or()oft,noerisrdtoawteinofcsinaeortoawayeetowkweurteieo.Amlcsptcrwlntbecdteurteieofcssybeoftepeofmsorcsofcsttarinitcntei.S.Tepsoftscraehyddtobeseadifaypnoftscrorteanofshpntoaypnorceisddidf]
[DELETED: yr,shdnslntattevyoftersoftscN2.TtSn3,IoC,b,adteseishdtordasf.SEI.()TecdssldintssnaeidinseI)Ayoftefgo,igtri,e,s,adssofi,e,ade,uss,wrteeeoftei,e,esadsspewntesccld)Al()A)Alfl()Alfl()A)Al(tllaokna,llaeorL)A)A)A)Al()B)B)Bl()B)Bl()B)B)Blf)Blf)B)Be()Be()C)Clfl()Clfl()Clfl()D]
[DELETED: )D)D)D)D)D)D)Dlb)D)E)E;Ee()E)E)Fds."dssaysentoeldadfrwhnoenolisinetursn55ofteflf,d,aca,21U.3,adttissyrdtoflbyoe()ormeoftefgm.Rtofteplpnofteplgpbya,wrorntfrsdinorontem.Sninoronteplgpwha,a,h,h,h,a,ornog.Sninorontepergwha,a,e,e,h,h,h,arnog.Rtofteaergwhayacmrorntfrsdinoronteacm;a.RtofteNlgpbyaralg)Flc)Fe()4lfl()2oo)Flfl()F)H)Ilfl()Ie()K)L)L)Mlfl()4lalf]
[DELETED: )3)3l()Me()Me()M)MP()M5(-()Nlf)N)N)N)N)Noee()Ol()Olf)Olf)O)Olf)Ola)Olmlf)Plfl()i)Plfl()b)Pl(]p)Poflf)Plfl()b)P)PP()P)P)P)P)Plf)P)P)P)P)Pe()R]
[DELETED: )Tlfl()Tl()T)T)u0()Vlfl()Zl()Ayoftefgomd,trs,isasofi,ussye,wrteeeoes,isadssofisispewntesld)A)A)B)Cem)C)C)D)D)D)Ee(thes)H)H)M)M)Mem)Mem)M)M)N)N)N)P)T)Hcs.Aym,c,meonttcsayqyoftefgh,trs,isadssofi,uss,wrteeeoftes,i,adssofisispewntesccldn(rpsossno,tetm""isteo,pnaci)D,oraycdntsdorldinarsettcnbefdfebyrtofoe()ormehswhara,flg)ors]
[DELETED: ,btntldt,csshasD,D,2)Meoraycdntsyedodinarsettcnbefdfmmyrtofoe()ormehnaswharalg)ors)i,btntldtsshasPAadD)5)5)Aeormewhahnsnontlr,igcsshasfdaeadm)3ya)3e()3e(oknasN4()p,adNlM,M,M)Ne(oknasN)p,adNyM)3ya)5e(oknas5ead5)Ae(eorn:e,3)i)A)B)De()De()I)Lcadd)M)()M)()M)()P)()P)()Nlb)()Nlb)()Pe(,1)()P)()P)Tsorscesoftesdintep,orintersesofC,srscs,d,adtriswhsrclseshastef.T,etfrtepdatolfdinilh,ornsingptadbyteUdSsfdaddga]
[DELETED: .∆csortst,adtroli,egdlinseoladedinerastgnceorinanolsnadgptadbyteU.FdadDgA.∆csortst,adtro.∆csortst,adiso.(eneoftessisntiys,csoftessofnldnofacpsa.[,aoknas6l()adisgs(1ord.Tefgscd.Aycdsyddfm(,c,a,or(,c,a,o,c,a,mrdlb,al(rd)cebysnattennafteiergorcetoaye,wrotfrsdinoronteiergtoaye,wrorntsdtoayetinoront,c,alr)(nintgmyi,btisntldt,hssha,srado.N1He(.1,e.11He(.El2e*(.(e(F.1e(;S.(.F,M-FA(l2.Ml2e(,A]
[DELETED: .Ml2e(.Ml2e(.Ml2e(.Ml2e(,5.Ml2e(.Ne(.Ne(;F.Ne(,5.Ne(.Nl1e(;C.Aycdsyddfm3ebysnattennamoftergtoaye,wrorntfrsdintepergtoaye,wrorndintenlrgtoaye.Aycdsyddfm1ebysnatte3nofteiergtoaye,wrorntfrsnteiergtoaye,wrorntsntenlrgtoaye.Aycdsyddfm3ebysnattennamoftergtoaye,wrorntfrsdinteiergtoaye,wrorntsdinteplrgtoaye.Aycdsyddfm2lbysnatte5noftcrgtoaye,wrorntsdieclrgtoaye.Aycdsyddfm3esewhsnattennamoeiergtoaye,wrorntfrsdinteiergtoayetadwrorndinteplrgtoaye.[.3l(]
[DELETED: .[,6,9,1e(P5)()Eeagofp:Ne()e;N)e,c,P)()Peagofp:1)-,P,P)()Teagofpe1,2gofp,T,T)()Tlf)()1)c]pearn)()Ssormmceofpgmsttcnpnorp)Ussyedorusldinarsym,c,meorpnwhcsayqftefgsshgadtetonteclnss,igiss,i,adssofiswrteofshs,i,adssofisispewntccld)Gahcad(eornsieG;g,4;4ca;smo;smo)Fm(oknasR,R)M)M)S.Ussyedorusldinars,aym,c,m,orpnwhcsayqyoftefgsshgastetoeclnss,igiss,i,adssofi)Ae(ca)Ax(eorn:a,2,or4,4x(;4)or()Ce(eorn:2,a,2eadn)Sdc.Ayc,etbnorcslduradts,syddfebysnatte1nwhe,nlortergs,wrornttecsfrmdinayoftefgw.Bysnintergsmtoayetwha,a,h,hlorhes,wrorntfrsdintergsyoe()ormeoruts]
[DELETED: .Bysnatte3nwhanacals.Bysnatte2onnamwha,blormlg,orbyinoftonnaminaccs)A*()A*()4*()Ee()F)Mb()Me(eorn:2,a,N,A,A,A3adU)Me()(x[)4*()4*()Ne(okna:B,1)N)N)Ne(okna:NN3.TtSn3,IoC,b,adteseishdtordasf.SEI.()SeIIslctoftedsars,bywroln,cnoruln,c,orbdned,ldintss)S,veonorcls.Uyedorusldinars,ayoftefgsswrpddyoriybyemssofveo,oriybymsofc,orbyacnofenadcls)Omado,adays,c,d,orpnofomoro,ega,d,n,n,n,neadtrrestigtef.Rwo.Ome.Omfde.Pdo.Gdo.Teofo.C.D.D.E]
[DELETED: .Eeh.H.H.M.M.O.O.O.T.T)Ays,c,d,orpntfwhiyetorilwhayoftessroinph()oftss,etttteslntieteieasofo)Ompyadpys)Calsadays,c,d,orpfcal,adays,c,d,orpfwhiscyetorilwhayoft,btslntietef.Ddcalsoresofcal,wsdontcnc;ore;o.[I)B)Me(e-iss,oli,asofoli)Ceofpysw(eceetofpyswinl,sdorprfmttcstepeasoeomp)Ayoftefgo,igtri,e,s,adssofi,wrteeeoftei,e,esadssispewntescc,ussyedorusldina)A)A)A)B)BkDe(ef)C)D)D)F)I)Ll(oknasl,lla,L)L)L)M)M]
[DELETED: )Me--I,4,4)Me--I,2,1ca)Nl()p)O)Pe()Pe--Ie--A,4)Pe--Ie--B,e)Pe--Ie--C,1ca)P)P)R)R)R)S)S.Ussyedorusldinars,aym,c,m,orpnwhcsayqyoftefgsshgastetoeclnss)A,iss,oli,adssofiso)L)M,iss,i,adssofisi)Peadiss)M)D.Ussyedorusldinars,aym,c,m,orpnwhcsayqyoftefgsshgadtetoeclnss,igiss,i,adssofi,wrteeeofshs,i,adssofisiewntesccld)A)G)P)P)S)Hcs)Ne..(rnefrn)(1CR12()Iep.Ussyedorudinars,aym,c,m,orphcsayqyoftefgs)Ieprtoaeadm)Aca)E]
[DELETED: )Lda)M)Mlf)N)Pca)P)P)Ptttaycnorcdcge,orayosssadi,orpeorisssadirp,orayofisssadiswhisprdgorordnisntacefrtepeoftss,usshseisp,d,orpdwhittodrtoarweittomem,aeorayodseinvnofsn3,IoC.Fsoftsp,tersofteumcsatslntaytoam,wrorrroforpscgteldssshpnp,d,orpswhittrtoarteorptwhittomeacds)Iepstope()1)1e()Ieprtof:4e()M)Tsorscesoftesdintep,orintersesofC,srscs,d,adtriswhslseshastef)T,etfrtepdatoftlfdinilh,ornsinadgpdbyteUdSsfdaddga)∆csortst,adtroli,egdlinseoladedinerastgnceorinanolsninadgpdbyteU.FdadDgA)∆csortst,adtroli)∆csortst,adisoli.(eneoftessisntiys,csoftes,rsoldnofacpsaec)[,anas6)adisgcis(1ord]
[DELETED: )Tefgscd)Aycdsyddfm(,c,a,or(,c,a,or(,c,a,mlordlbl(rd)cebysnattennasofteiergorcoaye,wrorntfrsdinoronteiergtoaye,wrorntsdtoayenorontec,c,alr)(ntergmyi,btisntldt,hssha,srado)Ne()1,e)11He()El2e*()(e(F)1e(;S)()F,M-FA(l2)Ml2e(,A)Ml2e()Ml2e()Ml2e()Ml2e(,5)Ml2e()Ne()Ne(;F)Ne(,5)Ne()Nl1e(;C]
[DELETED: )Aycdsyddfm3ebysnattennamoftepergtye,wrorntfrsdinteperoaye,wrorntsdintenlrgtye)Aycdsyddfm1ebysnatte3nofteieroaye,wrorntfrsdinteigtoaye,wrorntsdintenlroaye)Aycdsyddfm3ysnattennamofteiergtoaye,wrorntfrsdinteiergtoa,wrorntsdinteplrgtoaye)Aycdsyddfm2lbysnatte5noftepgtoaye,wrorntsdintecgtoaye)Aycdsyddfm3ewhsnattennamofteigtoaye,wrorntfrsdintergtoayetadwrorntsdintlrgtoaye)[)3l()[,6,9,1e(P5N4.TtSn3,IoC,b,adteseishdtordasf.PDASA--P.()Etasadbscrorcr9,te3,IoC,itisulfraypntomeord,orpswhittomeord,acds)Aypnwovstssnwhrtt)AcdsecdinseIwhiscdgoracdsecdinseItaspdfrinsn3,IoC,iyofafyaduncnmybeidfratfysnttoedlei,orfdntmetetdds(,orb)AyorcdsewhisancddinseI,oracdsecdieI,isgyofafyaduncnmybeidfrntmetnfe()y,fdntmetnfntdds(,orb]
[DELETED: )AsecdinseIVisgyofafduncnmybeidfrntmetnte(,fdntmetntntdds(,o)AsecdinssVadVIisgyofraduncnmybeidfrntmnoe()y,fdntmetnfetdd,orb)Etasadbytsc,itisulfraypntoc,d,orpswhittod,acts)Aypnwovstssnwhrtt)ActsecdinseIwhiscd,oractsecdins,isgyofafyaduncnmybeidftmetnfn()y,fdntmetntdds(,orb)AyorctsecdinsehisancdgcdinseIoractsecdinseIIisgyofafyancnmybeidfrntmetnfe()ydntmetnfntdds(,orb)ActsecdinseIVisgfafyaduncnmybeidfrntmnte()y,fdntmetntntdd,orb)ActsecdinssVadVIondctseisgyofamduncnmybeidfrntmetnoe(,fdntmetnfetdds(,orb)Itisulfraypntopsacdsstesewsoddyf,orptt,avnororofaprweaginteceofhlp,oretasoeadbytscror9,te3,IoC)AypnwovstssnadhsinhspcdsecdinseIwhisangoracdsecdinseIIisgyofyaduncnmybeidfrntmetns)y,orfdntmetnfntdds(,o)Aypnwovstssnadhsinhspcaddeisgyofafyaduncnmeidfrntmetnte()y,orfdntmetetdds(,orb)Aypnwovstssnadhsinhspndsewhisancdgcdinsetlcadd,oracdsecdinssI,I,VadVIisgyofamradu]
[DELETED: ntfmybeidfrntmetnoe()y,odntmetnoetdds(,orb)Itslbeulfraypntobeptatoronpfaypeweheksilcdssaebgmdorc,oraebghdfrd,t,d,a,u,ortobegna.Avnoftssnsldmtepsgyofamradunclbepdbyafeofntmetntehdds()atmetnny()dsintecyj,orb)Ifaypnisfdtopsm,whfrtepftssnslberdtoalpsoftepsoftsC,igteetoraypnofcswst,inanatgrtnte()otw,itslbeafyaduncnmybeidftmetnfe()y,orfdntmetntntdd,orb.Tepsoftssndontaytoapnagagtoadincewhtepsofcr9e3,IoC)Ifto()ormepscetoctayoeddisa,sdpsslbepdbyafeori,orbhmyntedtemmptpdfrteo,tnofwhwsteotoftec)Itisulfraypntomeordedcds"ortopswhittodea"dcds"Aypnwovstns,unc,begyofamraduntfslbepdbyafeofntmetnoetdds()adntmetnoe()yrintecyjrb)Itisulfraypntopsa"dc"Aypnwovstssns,unc,begyofamraduncntfslbdbyafeofntmetntehdds()adnetnsx()msintecyj,orb)Itisulfraypntocetobepdinayn,h,ororp,ortoptordeinacp,ayatorsnogfrsesds.Aypnwovstssnisgyomradslbepdintesemraspdinsn()oftss)Noclorcllyslbeidbyveoftronaypnrdurteumcdstwom,d,orpsanincefrueasapoororuebyardp,adinsn3,IoC,inteceofpeorr)Nopnurtscrslbeddsybyrnoftefttttedeuswecdinabeororcrwhallaydgteisoftei]
[DELETED: dsedeu.Tegdfhoftedtslbnieofftfrtetroff)Uncnofafyormrvnurtroruncnofafypttotergan1,IoC,ortemylgadilisofsn1,IoC,tectmyorrrcsidbylwetasinigtev.Lwetassli,btntbeldt,tosep,cyadcylweta,teofteaygladcyadcypgayossli,btntbeldt,teidfrtepfe,tladprdmfrlwetosadwtteceoftei,hsadt,adarieorpnesayi,irssofe.InteceofrttoteIep,temsslbepdtoteIosepeftiotedgaddgweurteieenfdcdinsn5,IoC.Inteceofrttoteoeofteayg,temsslbepoteglf.Acnfrtepsoftssnmstepnhspdgyorhsbnfdg,ngtefftej)orwdjN5.TtSn3,IoC,b,adteseishdtordasf.TG--MYS.()Etasadintscrorcr9,te3,IoC,adngtepsofsn3,IoC)Aypnwokym,d,orbsiss,orwoiskyinalorcep,oe()pdofmaorm,orte()msorm,asddinsn3,IoC,isgyof,whfyslbeknas"ginm"Ieqyofmai)Isoe()pdorm,btlstnfe()p,orcsofte()mapsormebtfrty()map,rsofteseorwtoep,shpnslbesdtoamymdtmofitofoe()yradfdntlstetdds()Isfe()psorm,btlstnte(,orcsoffy()mapsormebrtnoehd()map,rsofteorwtoftep,shpnslbesdtoymmfdtmofitofte()ydfdntlstntntdds()Iste()psorm,orcsofoeh)mapsorm,rsofteseorwftep,shpnslbesdtoamym]
[DELETED: mfdtmofitoffe()ysadfdntlnfntdds()Temmnrofysofitfrtgiaslbefn()y,adtemmfesefytdds()Frtepsoftss,tewtoftemsiswtwnsdorasddassnaspears,ustepsofsn()oftna)Aypnwokym,d,orbsiss,orwoiskyinalorcep,tt()gsormeofceorofaymeorsecgadeatofceisgyofafhfyslbeknas"ginc"Ifteq)Istt()gsorm,btlstntoh)g,shpnslbesdtoamymdtmofitofte()ysadfdntlntntdds()Istohd()gsorm,btlstnfrh)g,shpnslbesdtoamymmfdtmofitoffe()ysadfdntlnfntdds()Isfrhd()gsorm,shpnslbesdtoamymmfdtmofitoft)ysadfdntlstntetdd)Temmnrofysofitfrtnceslbel,adtemmfeslbeoehdds()Aypnwokymsorastomearaeisgyofafywhseknas"ginmearaebym"Aypncdoftginmraebyadmgslbesdtmymmfdtmofitofto()ysattoedfn()ysitadfdntlstntdds(.Aypncdoftginmearaebymgslbdtoamymmfdtmofitoff)ysadnttoedleitadfdntlstetdds(.Temmnrofysotfrtginmearaebgslbel,adtemmfeslbeoehdds()Aypnwokyd,orbsiotss,ooiskyinalorcepno,t)gsormeofmeoraeorofaymrsecgadeatofmeora]
[DELETED: eisgyofaf,whfyslbeknas"ginmeora"Ifteqyi)Istt()gsorm,btlstntoh)g,shpnslbesdtoamymdtmofitofte()ysadfdntlntntdds()Istohd()gsorm,btlstnfrh)g,shpnslbesdtoamymmfdtmofitoffe()ysadfdntlnfntdds()Isfrhd()gsorm,shpnslbesdtoamymmfdtmofitoft)ysadfdntlstntetdd)Temmnrofysofitfrtgieoraeslbel,adtemmflbeoehdtdds()Aypnwokym,d,bsiss,orwoiskyinalorcepftebdqsofayoftefgistomeorae(ye,m,mlf,pca,p,orp)asddinsn3,IoC,ora,meorpnwhcsadeqftes,isgyofafywhslbeknas"giniepsofmeora"Ieq)Ofeeisfehd()gsorm)Ofmeisof()ptorm)Ofmlfeisor()ptorm)Ofpcadisfehd()gsorm)Ofpeisfrhd()gsorm)Ofpeisfehd()gsormhpnslbesdtoamymmfdtmotoftn()ysadfdntlstntetdds(.Temmnrofysofirtginiepsofmeoraeinteqssdinps()th()ossn()slbel,adtemmfeslbeoehdtdds(.Ifteqyofpste()gsorm,btlstnfehd(,shpnslbesdtoatmofitofuotn()ysadfdntmetntetdd)Aypnwokym,dsorbsiot,orwoiskyinalorcepno,t)gsormeofhnorays,i,orstofani,orto()gsormeofaymeorsecdeatofayshseisgyofaf,w]
[DELETED: yslbeknas"ginh"Ifteqyi)Isto()gsorm,btlstnsn()g,snslbesdtoamymmfdtmofitofte()ysadfdntlstntnts()Issn()gsorm,btlstntt(,shpnslbesdtoamymmfmofitoftn()ysadfdntlstnfntdds()Istt()gsorm,shpnslbesdtoamymmfdtmofitoffn()ysadfdntlstntetdds()Temmnrofysofitfrtnhnslbel,adtemmfeslbeoehdds()Asdcnfraytgoeasddinsn()oftssnslrtinamymmfmttistettoerdurtss)Ngayorpnofl,whrttoanwoisfdtohevdtepsoftss,anofgtorteinorenofseslnes,d,orw,nrslshpnbeerpeprtosgtemymmfdtmofitpdintss.F,tectslntr)Aypnwoa,c,csorcswharpnorssarpntoctayatpdinsn()oftssnisgyofafyadispeasifhdaycdshpda)Frtepsofss()ad()oftssnttoftecdseasrdbytepnsgogitisdeiftewtasrdisgrtealwtoftecdsN6.TtSn2,IoC,b,adteseishdtordasf.D.Wnudintsc)Tetm"lr"msayd,cnofd,pym,vyb,orcfdsadori,ortnfrfdorccphispdorcdfrayalueetm,ormrtnfdidtoatteseorayfnoftebfasortnm.Tstmdsntiemdf)Tetm"dn"msayw,n,slord,oycnt,igteclfdofadrotaddgitfmttofo]
[DELETED: )Tetm"lf"msalmsorcnosttaeddoridfrdnfrueasfrfrmginf,frpyadasortnm,e)Udwessadpyadeeudsnshweorpyadssaentcycraentadwntemgofsn2,I,ormdwntemgofsn2,IoC)Ssmdadpdasshm,gnadhdaso)c,adpdasoe()mewnntadwemgofsn2,IoC,ormdwntgofsn2,IoC)Alh,etcyddlsadgsanntadwntemgofsn2,IoCrmdwntemgofsn2,IoC)Weorgds,s,s,c,h,h,wtodbtp,passadbtddmswnndwhormsadwnntadwntemfsn2,IoC,ormdwntemgofsn2,IoC)L,weorudaswnntadwntgofsn2,IoC,ormdwntemgofsn2,IoC)Alrswnntadwntemgofsn2,IoC,ormdwntemgofs,IoC.Alrsfrp,syp,asttieisfmilhpasddin2,IoC,adasddurtedf"fmtsorsce"ins)pttosn3,IoC,aentcda)Ilmlsswnntmdwharmdwnntadwntemgofsn2,I,ormdwntemgofsn2,IoC)Cnpgbsorpnw,idbedrinr,wtfrp,rdbyteerdyfmtefdprwnntadwntgofsn2,IoC,ormdwntemgofsn2,IoCed,byr,myetfmtsd,orfmssoftsc,csadilclcrsswnshc,csorssaentidwhormsadaentadagtotsofsn2,IoC,ormdwntemfsn2,IoC)Tetm"tf"msapnwoasanitcrfsclfdtoaspttoactwyslfdiss,f,oroepdtoshpdwyshpsrnisd,alorinp,byf,m,p,oratorqyofp]
[DELETED: )Tetm"af"msclfdttcsofameofclfsarfdi,ehbfwhismdagtotescisofteflp,edurorc.Cafddsntilfsttaeudasisinorclfdoradfrrlorfrd)Tetm""msteIodtofa)Tetm""mstedrofteIodtoeortedsada)Tetm""mstoorfrs,s,eeorclfsinoriotsseortos,f,oroepeclfdtoactf)Tetm""msaypnwod)Tetm""msayaeidfrueinted,c,m,t,orpnofdeinasonmnadasortnfdidtoatteseoranoftealb)Tetm"di"msehoftectmgupaclf)Tetm""msadyofw,p,orgrunoradtotecrinwhaclfdisddoronteieordyspwhwhaclfdi)Tetm""msallsadorw,p,ocmrunaclfdorayofiscsorwrogshclf.Tsisssadpncywsororidcri)Tetm""mstog,mxorb,orfsaclfdfrd)Tetm"df"msayfdttcsdgisidorpdfrtec,m,t,orpnofdeinasortnmnorttcsdgidtoatteseorayfnoftebyofasonm)Tetm""msanyo,hsicsds,eltotennofa,hgadeclcnadccces,cdh)Tetm"lf"msaclfdidtosymlesoricn)Tetm"ls"msaseofclfdtytedroranadatinaewhtepson2,IoC)Tetm""or""mspebyw)Tetm""isani,p,c,f,anada)Tetm""msayddalnymnornrteh)ofteo)t)Tetm"tf"msayclfdpdadddfrcnbydsadc]
[DELETED: )Tetm""msayptpdfrttorpnofdefrvyp,i,scadnlh,a,ssord)Tetm"tn"msteneofteclfdtsitastok,csorscu)Tetm""istgbys,d,n,m,p,l,ieorr,gtorayorvncganitinp)Tetm""msapnwotsbyp)Tetm""msttp,m,grdrworsaptorpsagtotepsofsn2,IoC)Tetm""or""ise)Tetm"yp"msayddalptnymdinaceort,shasbtntldtog,c,peb,m,f,tlf,g,ssadt)Tetm"yptf"msayclfdpdddfrcnbysyp)Tetm""msantwtoftotd()psa)Tetm"yb"msaybcpturvyp,igbtntldtoa,a,ghpsadbep)WsigtesrnrmyedadbeadtlpsortsadwsigteplmyietesN7.Aneyegt,wheyishdtoe,tsatslbeinflfeadetonadarieada]